Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream.
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
The formation or presence of a blood clot (THROMBUS) within a vein.
Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.
Agents that prevent clotting.
Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.
Inflammation of a vein associated with a blood clot (THROMBUS).
Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis.
Low-molecular-weight fragment of heparin, having a 4-enopyranosuronate sodium structure at the non-reducing end of the chain. It is prepared by depolymerization of the benzylic ester of porcine mucosal heparin. Therapeutically, it is used as an antithrombotic agent. (From Merck Index, 11th ed)
Bleeding or escape of blood from a vessel.
Tight coverings for the foot and leg that are worn to aid circulation in the legs, and prevent the formation of EDEMA and DEEP VEIN THROMBOSIS. PNEUMATIC COMPRESSION STOCKINGS serve a similar purpose especially for bedridden patients, and following surgery.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Instruments that generate intermittent forces, uniformed or graduated, to facilitate the emptying of VEINS. These devices are used to reduce limb EDEMA and prevent venous THROMBOEMBOLISM, such as deep vein thrombosis in the legs.
Mechanical devices inserted in the inferior vena cava that prevent the migration of blood clots from deep venous thrombosis of the leg.
Fixed drug combinations administered orally for contraceptive purposes.
The return of a sign, symptom, or disease after a remission.
A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.
A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
A hemostatic disorder characterized by a poor anticoagulant response to activated protein C (APC). The activated form of Factor V (Factor Va) is more slowly degraded by activated protein C. Factor V Leiden mutation (R506Q) is the most common cause of APC resistance.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
System established by the World Health Organization and the International Committee on Thrombosis and Hemostasis for monitoring and reporting blood coagulation tests. Under this system, results are standardized using the International Sensitivity Index for the particular test reagent/instrument combination used.
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.
A synthetic progestational hormone used often as the progestogenic component of combined oral contraceptive agents.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
A condition caused by one or more episodes of DEEP VEIN THROMBOSIS, usually the blood clots are lodged in the legs. Clinical features include EDEMA; PAIN; aching; heaviness; and MUSCLE CRAMP in the leg. When severe leg swelling leads to skin breakdown, it is called venous STASIS ULCER.
Unsaturated derivatives of the steroid androstane containing at least one double bond at any site in any of the rings.
The co-occurrence of pregnancy and a blood disease (HEMATOLOGIC DISEASES) which involves BLOOD CELLS or COAGULATION FACTORS. The hematologic disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
An absence or deficiency in PROTEIN C which leads to impaired regulation of blood coagulation. It is associated with an increased risk of severe or premature thrombosis. (Stedman's Med. Dict., 26th ed.)
An autosomal dominant disorder showing decreased levels of plasma protein S antigen or activity, associated with venous thrombosis and pulmonary embolism. PROTEIN S is a vitamin K-dependent plasma protein that inhibits blood clotting by serving as a cofactor for activated PROTEIN C (also a vitamin K-dependent protein), and the clinical manifestations of its deficiency are virtually identical to those of protein C deficiency. Treatment with heparin for acute thrombotic processes is usually followed by maintenance administration of coumarin drugs for the prevention of recurrent thrombosis. (From Harrison's Principles of Internal Medicine, 12th ed, p1511; Wintrobe's Clinical Hematology, 9th ed, p1523)
Radiographic visualization or recording of a vein after the injection of contrast medium.
Material used for wrapping or binding any part of the body.
A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.
Thiophenes are aromatic heterocyclic organic compounds containing a five-membered ring with four carbon atoms and one sulfur atom, which are found in various natural substances and synthesized for use in pharmaceuticals and agrochemicals.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Formation and development of a thrombus or blood clot in the blood vessel.
An amino acid formed in vivo by the degradation of dihydrouracil and carnosine. Since neuronal uptake and neuronal receptor sensitivity to beta-alanine have been demonstrated, the compound may be a false transmitter replacing GAMMA-AMINOBUTYRIC ACID. A rare genetic disorder, hyper-beta-alaninemia, has been reported.
I'm sorry for any confusion, but "Austria" is a country located in Central Europe and it is not a medical term or concept. Therefore, it doesn't have a medical definition.
Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.
Pregnenes with one double bond or more than three double bonds which have undergone ring contractions or are lacking carbon-18 or carbon-19..
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Oral contraceptives which owe their effectiveness to synthetic preparations.
Directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery.
A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233)
The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome.
The co-occurrence of pregnancy and a cardiovascular disease. The disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally estrogen or progesterone or both.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Strips of elastic material used to apply pressure to body parts to control EDEMA and aid circulation.
The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot.
Pyridine derivatives with one or more keto groups on the ring.
Replacement of the knee joint.
The giving of drugs, chemicals, or other substances by mouth.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
The restriction of the MOVEMENT of whole or part of the body by physical means (RESTRAINT, PHYSICAL) or chemically by ANALGESIA, or the use of TRANQUILIZING AGENTS or NEUROMUSCULAR NONDEPOLARIZING AGENTS. It includes experimental protocols used to evaluate the physiologic effects of immobility.
Elements of limited time intervals, contributing to particular results or situations.
The confinement of a patient in a hospital.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.
Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.
Replacement of the hip joint.
That branch of medicine dealing with the studies and effects of flight through the atmosphere or in space upon the human body and with the prevention or cure of physiological or psychological malfunctions arising from these effects. (from NASA Thesaurus)
Double-layered inflatable suits which, when inflated, exert pressure on the lower part of the wearer's body. The suits are used to improve or stabilize the circulatory state, i.e., to prevent hypotension, control hemorrhage, and regulate blood pressure. The suits are also used by pilots under positive acceleration.
'Hospital Bed Capacity, 300 to 499' is a term used to describe healthcare facilities that have a bed capacity ranging between three hundred to four hundred and ninety-nine beds, which enables them to accommodate and manage a substantial number of patients while providing essential medical services.'
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
Endogenous substances, usually proteins, that are involved in the blood coagulation process.
Procedures used to treat and correct deformities, diseases, and injuries to the MUSCULOSKELETAL SYSTEM, its articulations, and associated structures.
Blood-coagulation factor VIII. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.
Conformity in fulfilling or following official, recognized, or institutional requirements, guidelines, recommendations, protocols, pathways, or other standards.
An absence or reduced level of Antithrombin III leading to an increased risk for thrombosis.
The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
Polysaccharides are complex carbohydrates consisting of long, often branched chains of repeating monosaccharide units joined together by glycosidic bonds, which serve as energy storage molecules (e.g., glycogen), structural components (e.g., cellulose), and molecular recognition sites in various biological systems.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Preliminary administration of a drug preceding a diagnostic, therapeutic, or surgical procedure. The commonest types of premedication are antibiotics (ANTIBIOTIC PROPHYLAXIS) and anti-anxiety agents. It does not include PREANESTHETIC MEDICATION.
Morpholines are organic compounds containing a morpholine ring, which is a saturated six-membered heterocycle made up of four carbon atoms and two oxygen atoms (OCC1CCO), often used as functional groups in pharmaceuticals, agrochemicals, and materials science due to their versatile chemical properties.
Persons admitted to health facilities which provide board and room, for the purpose of observation, care, diagnosis or treatment.
A deficiency of blood coagulation factor V (known as proaccelerin or accelerator globulin or labile factor) leading to a rare hemorrhagic tendency known as Owren's disease or parahemophilia. It varies greatly in severity. Factor V deficiency is an autosomal recessive trait. (Dorland, 27th ed)
Disorders or diseases associated with PUERPERIUM, the six-to-eight-week period immediately after PARTURITION in humans.
Laboratory tests for evaluating the individual's clotting mechanism.
The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).
Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
Compounds with a BENZENE fused to IMIDAZOLES.
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
Oral contraceptives which owe their effectiveness to hormonal preparations.
The use of hormonal agents with estrogen-like activity in postmenopausal or other estrogen-deficient women to alleviate effects of hormone deficiency, such as vasomotor symptoms, DYSPAREUNIA, and progressive development of OSTEOPOROSIS. This may also include the use of progestational agents in combination therapy.
The vein accompanying the femoral artery in the same sheath; it is a continuation of the popliteal vein and becomes the external iliac vein.
Procedure to accelerate the ability of a patient to walk or move about by reducing the time to AMBULATION. It is characterized by a shorter period of hospitalization or recumbency than is normally practiced.
Intrauterine devices that release contraceptive agents.
Toluenes in which one hydrogen of the methyl group is substituted by an amino group. Permitted are any substituents on the benzene ring or the amino group.
A condition characterized by a chronically swollen limb, often a leg with stasis dermatitis and ulcerations. This syndrome can appear soon after phlebitis or years later. Postphlebitic syndrome is the result of damaged or incompetent venous valves in the limbs. Distended, tortuous VARICOSE VEINS are usually present. Leg pain may occur after long period of standing.
Disease having a short and relatively severe course.
Azetidines are saturated, organic compounds containing a 4-membered ring with two carbon atoms and two nitrogen atoms (one as a secondary amine), which can be found in certain pharmaceuticals and natural substances, although they are less common than other cyclic amines.
Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.
A heparin fraction with a mean molecular weight of 4500 daltons. It is isolated from porcine mucosal heparin and used as an antithrombotic agent. (From Merck Index, 11th ed)
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers.
The vitamin K-dependent cofactor of activated PROTEIN C. Together with protein C, it inhibits the action of factors VIIIa and Va. A deficiency in protein S; (PROTEIN S DEFICIENCY); can lead to recurrent venous and arterial thrombosis.
The use of chemical compounds to prevent the development of a specific disease.
The term "United States" in a medical context often refers to the country where a patient or study participant resides, and is not a medical term per se, but relevant for epidemiological studies, healthcare policies, and understanding differences in disease prevalence, treatment patterns, and health outcomes across various geographic locations.
I'm sorry for any confusion, but "Massachusetts" is a geographical location and not a medical term or concept. It is a state located in the northeastern region of the United States. If you have any medical questions or terms you would like me to define, please let me know!
A weight-carrying structure for navigation of the air that is supported either by its own buoyancy or by the dynamic action of the air against its surfaces. (Webster, 1973)
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
Measures aimed at providing appropriate supportive and rehabilitative services to minimize morbidity and maximize quality of life after a long-term disease or injury is present.
The presence of co-existing or additional diseases with reference to an initial diagnosis or with reference to the index condition that is the subject of study. Comorbidity may affect the ability of affected individuals to function and also their survival; it may be used as a prognostic indicator for length of hospital stay, cost factors, and outcome or survival.
Injection of an anesthetic into the nerves to inhibit nerve transmission in a specific part of the body.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases.
A measurement of the time needed for FIBRINOLYSIS to occur.
Surgical removal of an obstructing clot or foreign material which has been transported from a distant vessel by the bloodstream. Removal of a clot at its original site is called THROMBECTOMY.
Placement of an intravenous CATHETER in the subclavian, jugular, or other central vein.
Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY.
Bleeding within the SKULL induced by penetrating and nonpenetrating traumatic injuries, including hemorrhages into the tissues of CEREBRUM; BRAIN STEM; and CEREBELLUM; as well as into the epidural, subdural and subarachnoid spaces of the MENINGES.
Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.)
Specific practices for the prevention of disease or mental disorders in susceptible individuals or populations. These include HEALTH PROMOTION, including mental health; protective procedures, such as COMMUNICABLE DISEASE CONTROL; and monitoring and regulation of ENVIRONMENTAL POLLUTANTS. Primary prevention is to be distinguished from SECONDARY PREVENTION and TERTIARY PREVENTION.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.
Statistical models which describe the relationship between a qualitative dependent variable (that is, one which can take only certain discrete values, such as the presence or absence of a disease) and an independent variable. A common application is in epidemiology for estimating an individual's risk (probability of a disease) as a function of a given risk factor.
Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts.
Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN.
Fractures of the FEMUR HEAD; the FEMUR NECK; (FEMORAL NECK FRACTURES); the trochanters; or the inter- or subtrochanteric region. Excludes fractures of the acetabulum and fractures of the femoral shaft below the subtrochanteric region (FEMORAL FRACTURES).
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Surgery which could be postponed or not done at all without danger to the patient. Elective surgery includes procedures to correct non-life-threatening medical problems as well as to alleviate conditions causing psychological stress or other potential risk to patients, e.g., cosmetic or contraceptive surgery.
Recording changes in electrical impedance between electrodes placed on opposite sides of a part of the body, as a measure of volume changes in the path of the current. (Stedman, 25th ed)
Extracellular vesicles generated by the shedding of CELL MEMBRANE blebs.
I'm sorry for any confusion, but "Denmark" is not a medical term and does not have a medical definition. It is a country located in northern Europe. If you have any questions related to medicine or health, I would be happy to try to help answer them.
Strategy for the analysis of RANDOMIZED CONTROLLED TRIALS AS TOPIC that compares patients in the groups to which they were originally randomly assigned.
Surgical removal of an obstructing clot or foreign material from a blood vessel at the point of its formation. Removal of a clot arising from a distant site is called EMBOLECTOMY.

Acquired risk factors for venous thromboembolism in medical patients. (1/679)

Acute venous thromboembolism (VTE) is a serious and potentially fatal disorder, which often complicates the course of hospitalized patients, but may also affect ambulatory and otherwise healthy people. While the introduction of thromboprophylactic measures is expected to have reduced the occurrence of postoperative VTE, there is an increasing awareness of the importance of medical conditions in determining thromboembolic events. Among the conditions that predispose patients to VTE are increasing age, cancer and its treatment, prolonged immobility, stroke or paralysis, previous VTE, congestive heart failure, acute infection, pregnancy or puerperium, dehydration, hormonal treatment, varicose veins, long air travel, acute inflammatory bowel disease, rheumatologic disease, and nephrotic syndrome. Other factors that have recently been associated with an increased risk of VTE disorders include persistent elevation of D-dimer and atherosclerotic disease. Recognition of the incidence and clinical importance of thrombosis will most likely encourage more widespread use of antithrombotic prophylaxis in medical patients.  (+info)

Thrombosis and the antiphospholipid syndrome. (2/679)

The antiphospholipid syndrome is an antibody-mediated hypercoagulable state characterized by recurrent venous and arterial thromboembolic events. Several studies have determined that the frequency of antiphospholipid syndrome in patients presenting with a venous thromboembolic event is between 4% and 14%. Because of the high risk for recurrent thromboembolism in these patients, current recommendations suggest a longer, potentially lifelong, course of antithrombotic therapy following an initial event. Although most authorities agree on an extended course of therapy, considerable controversy surrounds the optimal target therapeutic INR for patients with antiphospholipid syndrome. For an initial venous thromboembolic event, a target INR of 2.0 to 3.0 is supported by two prospective, randomized clinical trials. In contrast, relatively limited data exist for an initial arterial thromboembolic event in patients who have the antiphospholipid syndrome, and therapeutic recommendations range from aspirin to warfarin with a high target INR. Recurrent thromboembolic events can be extremely difficult to treat, and some patients may benefit from the addition of immunosuppressive therapies. Importantly, as many as 50% of the initial thromboembolic events sustained by patients with antiphospholipid antibodies occur in the setting of additional, coincident prothrombotic risk factors, indicating the importance of addressing any additional risk factors, such as hypercholesterolemia, in these patients. Prospective studies are needed to address the role of thromboprophylactic strategies in asymptomatic individuals with antiphospholipid antibodies in the absence of additional risk factors.  (+info)

Prophylaxis of venous thrombosis in medical patients: A real-world perspective. (3/679)

BACKGROUND: Although low-molecular weight heparins (LMWH) have been proven to be efficacious for prophylaxis of venous thrombo-embolism (VTE) in non-surgical patients, their use and safety outside the setting of a clinical trial has not been investigated. OBJECTIVE: The objective of this survey was to determine the efficacy and safety of LMWH (enoxaparin) in the prevention of VTE in a study population comprising general medical patients. METHODS: The study involved an open-label, non-controlled, multicentre survey of any patient confined to bed due to medical illness, where the physician had made an independent decision to prescribe LMWH as prophylaxis for VTE. The demographic information and risk factors for venous thrombosis and dose of enoxaparin were recorded. Patients were assessed for clinical evidence of VTE. Only if this was present were further invasive investigations performed. Adverse events relating to the use of LMWH were recorded. RESULTS: Four hundred and seventy-one patients were enrolled from 53 centres. Five per cent of the patients were treated for up to and including three days, 4.4% for four days or less, 49.6% for six days or less, and a further 45.5 % for seven to 21 days. The most frequently prescribed dose was enoxaparin 40 mg once daily (86%). Of the enrolled patients, 28.2% had one risk factor and 69.8% had two or more risk factors for the development of VTE. The incidence of clinically suspected deep-vein thrombosis (DVT) or pulmonary embolism (PE) in this survey was three out of 457 patients at risk, ie, 0.66%. One serious adverse event occurred in an incorrectly enrolled surgical patient and 22 minor adverse events occurred that were thought by the enrolling physician to be related to the study drug. CONCLUSION: This survey was not designed to test for efficacy in DVT prevention. However the incidence of clinically identified DVT was low and there were no deaths from PE. This probably represents a considerable reduction in morbidity and mortality from that described in studies comparing LMWH with placebo. Enoxaparin may be used with confidence in a 'real-world' situation out of the confines of a study in which exclusions, inclusions and therapy are rigorously controlled.  (+info)

The association of alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism in the LITE study. (4/679)

INTRODUCTION: The alpha-fibrinogen Thr312Ala variant has been shown to influence clot structure through increased factor XIII cross-linking and formation of thicker fibrin fibers. However, the effect of this common variant on risk of venous thromboembolism (VTE) is unclear. This paper reports the association between the Thr312Ala variant and VTE in the LITE study. MATERIALS AND METHODS: 506 cases and 1014 controls frequency matched on age, sex, race, and study were drawn from two prospective studies and included in the analysis. Logistic regression was used to examine the association between Thr312Ala and VTE. RESULTS: In a logistic regression model minimally adjusted for the matching variables, the Thr312Ala TA and AA genotypes were associated with a significantly higher risk of VTE than the TT genotype (TA OR and 95% confidence interval 1.27 [1.01-1.60], AA OR 1.49 [1.00-2.22]). Associations were similar in analyses of PE and DVT considered separately and across racial and study subgroups. The association between alpha-fibrinogen Thr312Ala and VTE was modified by both BMI and the FXIII Val34Leu variant; the combination of elevated BMI or FXIII Val34Leu with alpha-fibrinogen Thr312Ala conveyed lower odds of VTE than would be expected by an additive or multiplicative model of individual risk factors. CONCLUSIONS: These results suggest that alpha-fibrinogen Thr312Ala is involved in the pathogenesis of VTE and that its action may be modified by other VTE risk factors.  (+info)

Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. (5/679)

Venous thromboembolism (VTE) is an important complication of major orthopaedic surgery of the lower limbs. Fondaparinux, a synthetic pentasaccharide and highly selective inhibitor of activated Factor Xa, is the first in a new class of antithrombotic agents. To determine the optimal dose in Japanese patients, double-blind, placebo-controlled, dose-ranging studies of fondaparinux were conducted in patients undergoing total knee replacement (TKR) or total hip replacement (THR) surgery. Patients were randomly assigned to receive a once-daily subcutaneous injection of fondaparinux (0.75, 1.5, 2.5, or 3.0 mg) or placebo in Study 1 (TKR) and Study 2 (THR). In Study 1, the incidence of VTE was 65.3% in the placebo group and was 34.2%, 21.3%, 16.2%, and 9.5% in the groups receiving 0.75, 1.5, 2.5, and 3.0 mg fondaparinux respectively. In Study 2, the incidence of VTE was 33.8% in the placebo group and was 24.2%, 4.6%, 7.4%, and 14.4% in the 0.75, 1.5, 2.5, and 3.0 mg fondaparinux groups respectively. Dose-response effects were observed in both studies; however, no statistically significant differences in major bleeding events were found among any groups. Fondaparinux proved to be a potent anticoagulant with a favourable benefit-to-risk ratio in the prevention of VTE in these study patients.  (+info)

Detection of venous thromboembolism by proteomic serum biomarkers. (6/679)

BACKGROUND: Available blood assays for venous thromboembolism (VTE) suffer from diminished specificity. Compared with single marker tests, such as D-dimer, a multi-marker strategy may improve diagnostic ability. We used direct mass spectrometry (MS) analysis of serum from patients with VTE to determine whether protein expression profiles would predict diagnosis. METHODS AND RESULTS: We developed a direct MS and computational approach to the proteomic analysis of serum. Using this new method, we analyzed serum from inpatients undergoing radiographic evaluation for VTE. In a balanced cohort of 76 patients, a neural network-based prediction model was built using a training subset of the cohort to first identify proteomic patterns of VTE. The proteomic patterns were then validated in a separate group of patients within the cohort. The model yielded a sensitivity of 68% and specificity of 89%, which exceeded the specificity of D-dimer assay tested by latex agglutination, ELISA, and immunoturbimetric methods (sensitivity/specificity of 63.2%/60.5%, 97.4%/21.1%, 97.4%/15.8%, respectively). We validated differences in protein expression between patients with and without VTE using more traditional gel-based analysis of the same serum samples. CONCLUSION: Protein expression analysis of serum using direct MS demonstrates potential diagnostic utility for VTE. This pilot study is the first such direct MS study to be applied to a cardiovascular disease. Differences in protein expression were identified and subsequently validated in a separate group of patients. The findings in this initial cohort can be evaluated in other independent cohorts, including patients with inflammatory conditions and chronic (but not acute) VTE, for the diagnosis of VTE.  (+info)

The use of enoxaparin to prevent venous thromboembolism in patients undergoing radical retropubic prostatectomy: feasibility and utility. (7/679)

OBJECTIVE: To assess the utility of enoxaparin in prevention of venous thromboembolism (VTE) in men poorly compliant with pneumatic compression stockings (PCS) in the immediate postoperative period after a radical retropubic prostatectomy (RP). MATERIALS AND METHODS: This retrospective study included 47 men who underwent RP at an inner-city tertiary care hospital. All patients were started on enoxaparin 40 mg subcutaneously 6-8 hours postoperatively and daily while hospitalized. Preoperative, operative, and postoperative data were collected and analyzed. Median follow-up was 18 months. RESULTS: Median patient age was 64 +/- 7 years, median prostate-specific antigen level was 4.9 ng/mL and median prostate biopsy-determined Gleason score was 6. Forty-one men (87%) underwent a pelvic lymph node dissection. Median operative time was 181 minutes (range 164-450 minutes). Median estimated blood loss was 700 mL. Approximately 36% of the men wore PCS the recommended > 19 hours/day. On average PCS were worn 10.3 +/- 7.5 hours/day. Postoperative complications were not increased in this cohort. Two patients developed pulmonary embolism requiring long-term anticoagulation. There were no mortalities. CONCLUSIONS: In men non-compliant with PCS, initiation of enoxaparin in the immediate postoperative setting was well-tolerated and maintained a low (4%) rate of VTE. Thus, enoxaparin may be useful in adjunct with PCS in these patients.  (+info)

Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. (8/679)

BACKGROUND: The aim was to investigate the outcomes associated with venous thromboembolism (VTE) among irresectable pancreatic cancer patients. METHODS: This is a follow-up study of consecutive irresectable cancer patients, treated and followed up in clinical trials between December 2001 and December 2004 in order to evaluate the prognostic impact of symptomatic VTE on clinical outcomes, such as response to treatment, progression-free survival (PFS) and overall survival (OS). RESULTS: Among 227 irresectable pancreatic cancer patients, with Eastern Cooperative Oncology Group performance status (ECOG-PS) < or = 2, 59 (26.0%) patients developed a VTE. A synchronous VTE occurred in 28 (12.3%) patients, while a VTE during chemotherapy was observed in 15 (6.6%) patients, and 16 (7.0%) patients experienced both events. Presence of synchronous VTE was associated with a higher probability of not responding to treatment (odds ratio 2.98, 95% CI 1.42-6.27, P = 0.004), but showed no effect on both PFS and OS at least at multivariate analysis. Occurrence of a VTE during chemotherapy showed a statistically significant effect on PFS (hazard ratio [HR] 2.59, 95% CI 1.69-3.97, P < 0.0001) and OS (HR 1.64, 95%CI 1.04-2.58, P = 0.032). CONCLUSIONS: Our data suggest that the occurrence of VTE may be associated with a reduced response rate and a shorter PFS and OS among patients with irresectable pancreatic cancer. In these patients the development of VTE may reflect the presence of a biologically more aggressive cancer that in turn leads to a worse prognosis.  (+info)

Venous Thromboembolism (VTE) is a medical condition that includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT is a blood clot that forms in the deep veins, usually in the legs, while PE occurs when a clot breaks off and travels to the lungs, blocking a pulmonary artery or one of its branches. This condition can be life-threatening if not diagnosed and treated promptly.

The medical definition of Venous Thromboembolism is:

"The formation of a blood clot (thrombus) in a deep vein, most commonly in the legs, which can then dislodge and travel to the lungs, causing a potentially life-threatening blockage of the pulmonary artery or one of its branches (pulmonary embolism). VTE is a complex disorder resulting from an interplay of genetic and environmental factors that affect the balance between thrombosis and fibrinolysis."

Some common risk factors for VTE include immobility, surgery, trauma, cancer, hormonal therapy, pregnancy, advanced age, and inherited or acquired thrombophilia. Symptoms of DVT may include swelling, pain, warmth, and redness in the affected limb, while symptoms of PE can range from shortness of breath and chest pain to coughing up blood or even sudden death. Diagnosis typically involves a combination of clinical assessment, imaging studies (such as ultrasound, CT scan, or MRI), and laboratory tests (such as D-dimer). Treatment usually includes anticoagulation therapy to prevent further clot formation and reduce the risk of recurrence.

Thromboembolism is a medical condition that refers to the obstruction of a blood vessel by a thrombus (blood clot) that has formed elsewhere in the body and then been transported by the bloodstream to a narrower vessel, where it becomes lodged. This process can occur in various parts of the body, leading to different types of thromboembolisms:

1. Deep Vein Thrombosis (DVT): A thrombus forms in the deep veins, usually in the legs or pelvis, and then breaks off and travels to the lungs, causing a pulmonary embolism.
2. Pulmonary Embolism (PE): A thrombus formed elsewhere, often in the deep veins of the legs, dislodges and travels to the lungs, blocking one or more pulmonary arteries. This can lead to shortness of breath, chest pain, and potentially life-threatening complications if not treated promptly.
3. Cerebral Embolism: A thrombus formed in another part of the body, such as the heart or carotid artery, dislodges and travels to the brain, causing a stroke or transient ischemic attack (TIA).
4. Arterial Thromboembolism: A thrombus forms in an artery and breaks off, traveling to another part of the body and blocking blood flow to an organ or tissue, leading to potential damage or loss of function. Examples include mesenteric ischemia (intestinal damage due to blocked blood flow) and retinal artery occlusion (vision loss due to blocked blood flow in the eye).

Prevention, early detection, and appropriate treatment are crucial for managing thromboembolism and reducing the risk of severe complications.

Venous thrombosis is a medical condition characterized by the formation of a blood clot (thrombus) in the deep veins, often in the legs (deep vein thrombosis or DVT), but it can also occur in other parts of the body such as the arms, pelvis, or lungs (pulmonary embolism).

The formation of a venous thrombus can be caused by various factors, including injury to the blood vessel wall, changes in blood flow, and alterations in the composition of the blood. These factors can lead to the activation of clotting factors and platelets, which can result in the formation of a clot that blocks the vein.

Symptoms of venous thrombosis may include swelling, pain, warmth, and redness in the affected area. In some cases, the clot can dislodge and travel to other parts of the body, causing potentially life-threatening complications such as pulmonary embolism.

Risk factors for venous thrombosis include advanced age, obesity, smoking, pregnancy, use of hormonal contraceptives or hormone replacement therapy, cancer, recent surgery or trauma, prolonged immobility, and a history of previous venous thromboembolism. Treatment typically involves the use of anticoagulant medications to prevent further clotting and dissolve existing clots.

A pulmonary embolism (PE) is a medical condition that occurs when a blood clot, often formed in the deep veins of the legs (deep vein thrombosis), breaks off and travels to the lungs, blocking one or more pulmonary arteries. This blockage can lead to various symptoms such as shortness of breath, chest pain, rapid heart rate, and coughing up blood. In severe cases, it can cause life-threatening complications like low oxygen levels, hypotension, and even death if not promptly diagnosed and treated with anticoagulant medications or thrombolytic therapy to dissolve the clot.

Anticoagulants are a class of medications that work to prevent the formation of blood clots in the body. They do this by inhibiting the coagulation cascade, which is a series of chemical reactions that lead to the formation of a clot. Anticoagulants can be given orally, intravenously, or subcutaneously, depending on the specific drug and the individual patient's needs.

There are several different types of anticoagulants, including:

1. Heparin: This is a naturally occurring anticoagulant that is often used in hospitalized patients who require immediate anticoagulation. It works by activating an enzyme called antithrombin III, which inhibits the formation of clots.
2. Low molecular weight heparin (LMWH): LMWH is a form of heparin that has been broken down into smaller molecules. It has a longer half-life than standard heparin and can be given once or twice daily by subcutaneous injection.
3. Direct oral anticoagulants (DOACs): These are newer oral anticoagulants that work by directly inhibiting specific clotting factors in the coagulation cascade. Examples include apixaban, rivaroxaban, and dabigatran.
4. Vitamin K antagonists: These are older oral anticoagulants that work by inhibiting the action of vitamin K, which is necessary for the formation of clotting factors. Warfarin is an example of a vitamin K antagonist.

Anticoagulants are used to prevent and treat a variety of conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation, and prosthetic heart valve thrombosis. It is important to note that anticoagulants can increase the risk of bleeding, so they must be used with caution and regular monitoring of blood clotting times may be required.

Low-molecular-weight heparin (LMWH) is a type of heparin used as an anticoagulant, which refers to a group of medications that prevent the formation of blood clots. Heparin is a naturally occurring substance in the body, and low-molecular-weight heparins are obtained through the depolymerization of standard heparin.

LMWH has a lower molecular weight than standard heparin, which results in several pharmacological differences. LMWHs have a more predictable dose response, longer half-life, and higher bioavailability when administered subcutaneously compared to standard heparin. They also exhibit greater anti-factor Xa activity relative to their antithrombin (anti-IIa) activity, which contributes to their anticoagulant effects.

LMWHs are used for the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and other thromboembolic disorders. Common LMWHs include enoxaparin, dalteparin, tinzaparin, and nadroparin.

It is essential to monitor the patient's kidney function when using LMWH since they are primarily cleared by the kidneys. In patients with renal impairment, dose adjustments or alternative anticoagulants may be necessary to reduce the risk of bleeding complications.

Thrombophilia is a medical condition characterized by an increased tendency to form blood clots (thrombi) due to various genetic or acquired abnormalities in the coagulation system. These abnormalities can lead to a hypercoagulable state, which can cause thrombosis in both veins and arteries. Commonly identified thrombophilias include factor V Leiden mutation, prothrombin G20210A mutation, antithrombin deficiency, protein C deficiency, and protein S deficiency.

Acquired thrombophilias can be caused by various factors such as antiphospholipid antibody syndrome (APS), malignancies, pregnancy, oral contraceptive use, hormone replacement therapy, and certain medical conditions like inflammatory bowel disease or nephrotic syndrome.

It is essential to diagnose thrombophilia accurately, as it may influence the management of venous thromboembolism (VTE) events and guide decisions regarding prophylactic anticoagulation in high-risk situations.

Thrombophlebitis is a medical condition characterized by the inflammation and clotting of blood in a vein, usually in the legs. The term thrombophlebitis comes from two words: "thrombo" which means blood clot, and "phlebitis" which refers to inflammation of the vein.

The condition can occur in superficial or deep veins. Superficial thrombophlebitis affects the veins just below the skin's surface, while deep vein thrombophlebitis (DVT) occurs in the deeper veins. DVT is a more serious condition as it can lead to complications such as pulmonary embolism if the blood clot breaks off and travels to the lungs.

Symptoms of thrombophlebitis may include redness, warmth, pain, swelling, or discomfort in the affected area. In some cases, there may be visible surface veins that are hard, tender, or ropy to touch. If left untreated, thrombophlebitis can lead to chronic venous insufficiency and other long-term complications. Treatment typically involves medications such as anticoagulants, antiplatelet agents, or thrombolytics, along with compression stockings and other supportive measures.

Fibrin(ogen) degradation products (FDPs) are a group of proteins that result from the breakdown of fibrinogen and fibrin, which are key components of blood clots. This process occurs during the normal physiological process of fibrinolysis, where clots are dissolved to maintain blood flow.

FDPs can be measured in the blood as a marker for the activation of the coagulation and fibrinolytic systems. Elevated levels of FDPs may indicate the presence of a disorder that causes abnormal clotting or bleeding, such as disseminated intravascular coagulation (DIC), deep vein thrombosis (DVT), pulmonary embolism (PE), or certain types of cancer.

It is important to note that FDPs are not specific to any particular disorder and their measurement should be interpreted in conjunction with other clinical and laboratory findings.

Enoxaparin is a low molecular weight heparin (LMWH) medication that is used as an anticoagulant to prevent and treat blood clots. It works by binding to and inhibiting the activity of factor Xa, a clotting factor in the blood. This helps to reduce the risk of clot formation and can help to prevent conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Enoxaparin is typically given by injection under the skin (subcutaneously) and is available under the brand names Lovenox and Clexane, among others. It is important to follow the instructions of a healthcare professional when using enoxaparin, as it can increase the risk of bleeding.

Hemorrhage is defined in the medical context as an excessive loss of blood from the circulatory system, which can occur due to various reasons such as injury, surgery, or underlying health conditions that affect blood clotting or the integrity of blood vessels. The bleeding may be internal, external, visible, or concealed, and it can vary in severity from minor to life-threatening, depending on the location and extent of the bleeding. Hemorrhage is a serious medical emergency that requires immediate attention and treatment to prevent further blood loss, organ damage, and potential death.

Compression stockings are a specialized type of hosiery that applies pressure to your legs, promoting better blood flow. They are tightest at the ankle and gradually become less constrictive up the leg. This gradient compression helps to counteract the force of gravity and promote venous return, reducing the pooling of blood in the lower extremities.

Compression stockings are often used to help prevent or treat various conditions related to poor circulation, including:

1. Varicose veins: Enlarged, swollen, and twisting veins that are easily visible just under the surface of the skin.
2. Deep vein thrombosis (DVT): A blood clot that forms in the deep veins, usually in the legs. Compression stockings can help reduce the risk of DVT after certain surgeries or during long periods of immobilization.
3. Edema: Swelling in the legs and ankles due to fluid buildup.
4. Chronic venous insufficiency: A condition where the veins have difficulty returning blood from the legs back to the heart, leading to symptoms like leg pain, swelling, and skin changes.
5. Post-thrombotic syndrome (PTS): A long-term complication of DVT characterized by chronic leg pain, swelling, and skin ulcers. Compression stockings can help manage symptoms and prevent further complications.

There are different levels of compression available, ranging from mild (15-20 mmHg) to extra firm (50-60 mmHg). Your healthcare provider will recommend the appropriate level based on your specific condition and needs. It is essential to wear compression stockings correctly for them to be effective and avoid skin irritation or other complications.

Warfarin is a anticoagulant medication that works by inhibiting the vitamin K-dependent activation of several coagulation factors (factors II, VII, IX, and X). This results in prolonged clotting times and reduced thrombus formation. It is commonly used to prevent and treat blood clots in conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Warfarin is also known by its brand names Coumadin and Jantoven.

It's important to note that warfarin has a narrow therapeutic index, meaning that the difference between an effective dose and a toxic one is small. Therefore, it requires careful monitoring of the patient's coagulation status through regular blood tests (INR) to ensure that the dosage is appropriate and to minimize the risk of bleeding complications.

Factor V, also known as proaccelerin or labile factor, is a protein involved in the coagulation cascade, which is a series of chemical reactions that leads to the formation of a blood clot. Factor V acts as a cofactor for the activation of Factor X to Factor Xa, which is a critical step in the coagulation cascade.

When blood vessels are damaged, the coagulation cascade is initiated to prevent excessive bleeding. During this process, Factor V is activated by thrombin, another protein involved in coagulation, and then forms a complex with activated Factor X and calcium ions on the surface of platelets or other cells. This complex converts prothrombin to thrombin, which then converts fibrinogen to fibrin to form a stable clot.

Deficiency or dysfunction of Factor V can lead to bleeding disorders such as hemophilia B or factor V deficiency, while mutations in the gene encoding Factor V can increase the risk of thrombosis, as seen in the Factor V Leiden mutation.

Medical Definition:

"Risk factors" are any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury. They can be divided into modifiable and non-modifiable risk factors. Modifiable risk factors are those that can be changed through lifestyle choices or medical treatment, while non-modifiable risk factors are inherent traits such as age, gender, or genetic predisposition. Examples of modifiable risk factors include smoking, alcohol consumption, physical inactivity, and unhealthy diet, while non-modifiable risk factors include age, sex, and family history. It is important to note that having a risk factor does not guarantee that a person will develop the disease, but rather indicates an increased susceptibility.

Intermittent Pneumatic Compression (IPC) devices are medical devices that use inflatable garments to apply controlled pressure in a rhythmic, intermittent manner to the extremities of the body, most commonly used on the legs. These devices are designed to help improve venous and lymphatic flow, reduce edema (swelling), and prevent the formation of blood clots (deep vein thrombosis) in patients who are at risk.

The IPC device typically consists of a pump, hoses, and an air-filled garment that covers the affected limb. The pump regulates the pressure and inflation pattern, while the garment applies pressure to the limb. The compression cycle usually starts with low pressure and gradually increases to a peak pressure before decreasing again. This process is repeated at regular intervals, providing intermittent compression that mimics natural muscle contractions and helps promote blood flow.

IPC devices are often used in clinical settings such as hospitals and rehabilitation centers, but they can also be prescribed for home use. They are commonly recommended for patients who have undergone surgery, experienced trauma, or have conditions that increase their risk of developing blood clots, such as prolonged immobilization, varicose veins, or certain medical disorders.

It is essential to follow the healthcare provider's instructions when using IPC devices and report any discomfort, pain, or unusual symptoms during treatment.

Vena cava filters are medical devices that are implanted into the inferior vena cava, which is the largest vein in the body that returns blood from the lower half of the body to the heart. These filters are designed to trap blood clots that form in the deep veins of the legs (deep vein thrombosis or DVT) and prevent them from traveling to the lungs (pulmonary embolism or PE), which can be a life-threatening condition.

The filter is typically implanted using a catheter-based procedure, and it has legs or arms that extend out to trap the blood clots as they flow through the vein. Over time, the trapped clots may dissolve on their own or become organized and incorporated into the wall of the vein.

Vena cava filters are typically used in patients who are at high risk for PE but cannot take anticoagulation medication or have failed anticoagulation therapy. However, there is some controversy surrounding the use of these devices due to concerns about their long-term safety and effectiveness.

Oral combined contraceptives, also known as "the pill," are a type of hormonal birth control that contain a combination of synthetic estrogen and progestin. These hormones work together to prevent ovulation (the release of an egg from the ovaries), thicken cervical mucus to make it harder for sperm to reach the egg, and thin the lining of the uterus to make it less likely for a fertilized egg to implant.

Combined oral contraceptives come in various brands and forms, such as monophasic, biphasic, and triphasic pills. Monophasic pills contain the same amount of hormones in each active pill, while biphasic and triphasic pills have varying amounts of hormones in different phases of the cycle.

It is important to note that oral combined contraceptives do not protect against sexually transmitted infections (STIs) and should be used in conjunction with condoms for safer sex practices. Additionally, there are potential risks and side effects associated with oral combined contraceptives, including an increased risk of blood clots, stroke, and heart attack, especially in women who smoke or have certain medical conditions. It is essential to consult a healthcare provider before starting any hormonal birth control method to determine if it is safe and appropriate for individual use.

Recurrence, in a medical context, refers to the return of symptoms or signs of a disease after a period of improvement or remission. It indicates that the condition has not been fully eradicated and may require further treatment. Recurrence is often used to describe situations where a disease such as cancer comes back after initial treatment, but it can also apply to other medical conditions. The likelihood of recurrence varies depending on the type of disease and individual patient factors.

Prothrombin is a protein present in blood plasma, and it's also known as coagulation factor II. It plays a crucial role in the coagulation cascade, which is a complex series of reactions that leads to the formation of a blood clot.

When an injury occurs, the coagulation cascade is initiated to prevent excessive blood loss. Prothrombin is converted into its active form, thrombin, by another factor called factor Xa in the presence of calcium ions, phospholipids, and factor Va. Thrombin then catalyzes the conversion of fibrinogen into fibrin, forming a stable clot.

Prothrombin levels can be measured through a blood test, which is often used to diagnose or monitor conditions related to bleeding or coagulation disorders, such as liver disease or vitamin K deficiency.

Vitamin K is a fat-soluble vitamin that plays a crucial role in blood clotting and bone metabolism. It is essential for the production of several proteins involved in blood clotting, including factor II (prothrombin), factor VII, factor IX, and factor X. Additionally, Vitamin K is necessary for the synthesis of osteocalcin, a protein that contributes to bone health by regulating the deposition of calcium in bones.

There are two main forms of Vitamin K: Vitamin K1 (phylloquinone), which is found primarily in green leafy vegetables and some vegetable oils, and Vitamin K2 (menaquinones), which is produced by bacteria in the intestines and is also found in some fermented foods.

Vitamin K deficiency can lead to bleeding disorders such as hemorrhage and excessive bruising. While Vitamin K deficiency is rare in adults, it can occur in newborns who have not yet developed sufficient levels of the vitamin. Therefore, newborns are often given a Vitamin K injection shortly after birth to prevent bleeding problems.

Heparin is defined as a highly sulfated glycosaminoglycan (a type of polysaccharide) that is widely present in many tissues, but is most commonly derived from the mucosal tissues of mammalian lungs or intestinal mucosa. It is an anticoagulant that acts as an inhibitor of several enzymes involved in the blood coagulation cascade, primarily by activating antithrombin III which then neutralizes thrombin and other clotting factors.

Heparin is used medically to prevent and treat thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and certain types of heart attacks. It can also be used during hemodialysis, cardiac bypass surgery, and other medical procedures to prevent the formation of blood clots.

It's important to note that while heparin is a powerful anticoagulant, it does not have any fibrinolytic activity, meaning it cannot dissolve existing blood clots. Instead, it prevents new clots from forming and stops existing clots from growing larger.

Activated Protein C (APC) resistance is a condition in which the body's natural anticoagulant system is impaired, leading to an increased risk of thrombosis or blood clot formation. APC is an enzyme that plays a crucial role in regulating blood coagulation by inactivating clotting factors Va and VIIIa.

APC resistance is most commonly caused by a genetic mutation in the Factor V gene, known as Factor V Leiden. This mutation results in the production of a variant form of Factor V called Factor V Leiden, which is resistant to APC-mediated inactivation. As a result, the body's ability to regulate blood clotting is impaired, leading to an increased risk of thrombosis.

APC resistance can be measured by performing a functional assay that compares the activity of APC in normal plasma versus plasma from a patient with suspected APC resistance. The assay measures the rate of inactivation of Factor Va by APC, and a reduced rate of inactivation indicates APC resistance.

It is important to note that not all individuals with APC resistance will develop thrombosis, and other factors such as age, obesity, pregnancy, oral contraceptive use, and smoking can increase the risk of thrombosis in individuals with APC resistance.

In epidemiology, the incidence of a disease is defined as the number of new cases of that disease within a specific population over a certain period of time. It is typically expressed as a rate, with the number of new cases in the numerator and the size of the population at risk in the denominator. Incidence provides information about the risk of developing a disease during a given time period and can be used to compare disease rates between different populations or to monitor trends in disease occurrence over time.

Dalteparin is a low molecular weight heparin (LMWH) medication that is used as an anticoagulant to prevent and treat blood clots. It works by binding to an enzyme called antithrombin III and enhancing its ability to inhibit clotting factors in the blood.

Dalteparin is available under the brand name Fragmin and is administered subcutaneously (under the skin) once or twice a day, depending on the indication and dosage prescribed by a healthcare professional. Common side effects of dalteparin include bleeding, bruising, pain at the injection site, and elevated liver enzymes.

As with all medications, it is important to use dalteparin only under the supervision of a healthcare provider and to follow their instructions carefully.

The International Normalized Ratio (INR) is a standardized measurement of the prothrombin time (PT), which is the time it takes for blood to clot. The INR is used to monitor and regulate the effects of anticoagulant medications, such as warfarin, that affect the blood's ability to clot.

The INR is calculated by dividing the patient's PT by a control value (the PT of normal, healthy blood), raised to the power of a sensitivity factor called the International Sensitivity Index (ISI). The ISI is specific to the thromboplastin reagent used in the PT assay.

The INR provides a consistent and comparable way to monitor anticoagulation therapy across different laboratories, regardless of the thromboplastin reagent used. This helps ensure that patients receive appropriate doses of anticoagulant medications and reduces the risk of bleeding or clotting complications.

In general, an INR range of 2.0 to 3.0 is recommended for most people taking anticoagulants for conditions such as atrial fibrillation, deep vein thrombosis, or pulmonary embolism. However, the target INR range may vary depending on individual patient factors and medical indications.

Fibrinolytic agents are medications that dissolve or break down blood clots by activating plasminogen, which is converted into plasmin. Plasmin is a proteolytic enzyme that degrades fibrin, the structural protein in blood clots. Fibrinolytic agents are used medically to treat conditions such as acute ischemic stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction (heart attack) by restoring blood flow in occluded vessels. Examples of fibrinolytic agents include alteplase, reteplase, and tenecteplase. It is important to note that these medications carry a risk of bleeding complications and should be administered with caution.

Desogestrel is a synthetic form of progestin, which is a female sex hormone. It is used in various forms of hormonal contraception such as birth control pills, patches, and vaginal rings to prevent pregnancy. Desogestrel works by preventing ovulation (the release of an egg from the ovaries), thickening cervical mucus to make it harder for sperm to reach the egg, and thinning the lining of the uterus to make it less likely for a fertilized egg to implant.

Desogestrel is also used in some hormone replacement therapies (HRT) to treat symptoms of menopause such as hot flashes and vaginal dryness. It may be prescribed alone or in combination with estrogen.

Like all hormonal contraceptives, desogestrel has potential side effects, including irregular menstrual bleeding, headaches, mood changes, breast tenderness, and nausea. In rare cases, it may also increase the risk of blood clots, stroke, or heart attack. It is important to discuss the risks and benefits of desogestrel with a healthcare provider before using it.

Postoperative complications refer to any unfavorable condition or event that occurs during the recovery period after a surgical procedure. These complications can vary in severity and may include, but are not limited to:

1. Infection: This can occur at the site of the incision or inside the body, such as pneumonia or urinary tract infection.
2. Bleeding: Excessive bleeding (hemorrhage) can lead to a drop in blood pressure and may require further surgical intervention.
3. Blood clots: These can form in the deep veins of the legs (deep vein thrombosis) and can potentially travel to the lungs (pulmonary embolism).
4. Wound dehiscence: This is when the surgical wound opens up, which can lead to infection and further complications.
5. Pulmonary issues: These include atelectasis (collapsed lung), pneumonia, or respiratory failure.
6. Cardiovascular problems: These include abnormal heart rhythms (arrhythmias), heart attack, or stroke.
7. Renal failure: This can occur due to various reasons such as dehydration, blood loss, or the use of certain medications.
8. Pain management issues: Inadequate pain control can lead to increased stress, anxiety, and decreased mobility.
9. Nausea and vomiting: These can be caused by anesthesia, opioid pain medication, or other factors.
10. Delirium: This is a state of confusion and disorientation that can occur in the elderly or those with certain medical conditions.

Prompt identification and management of these complications are crucial to ensure the best possible outcome for the patient.

Postthrombotic syndrome (PTS), also known as postphlebitic syndrome, is a chronic complication that can occur after deep vein thrombosis (DVT). It's characterized by a combination of symptoms including pain, swelling, cramping, itching, and skin changes in the affected limb. PTS happens when the damaged valves in the veins are unable to properly move blood back to the heart, leading to venous hypertension and fluid accumulation in the lower extremities.

The symptoms of PTS can vary in severity, but they often worsen with prolonged standing or sitting. In some cases, patients may develop open sores (ulcers) on the skin, particularly around the ankles. The risk of developing PTS is higher in individuals who have experienced a recurrent DVT, those with more extensive clotting, and those who do not receive appropriate anticoagulation therapy after their initial DVT diagnosis.

Preventive measures such as early mobilization, use of compression stockings, and maintaining adequate anticoagulation can help reduce the risk of developing PTS following a DVT.

Androstenes are a group of steroidal compounds that are produced and released by the human body. They are classified as steroids because they contain a characteristic carbon skeleton, called the sterane ring, which consists of four fused rings arranged in a specific structure. Androstenes are derived from cholesterol and are synthesized in the gonads (testes and ovaries), adrenal glands, and other tissues.

The term "androstene" refers specifically to compounds that contain a double bond between the 5th and 6th carbon atoms in the sterane ring. This double bond gives these compounds their characteristic chemical properties and distinguishes them from other steroidal compounds.

Androstenes are important in human physiology because they serve as precursors to the synthesis of sex hormones, such as testosterone and estrogen. They also have been found to play a role in the regulation of various bodily functions, including sexual behavior, mood, and cognition.

Some examples of androstenes include androstenedione, which is a precursor to both testosterone and estrogen; androstenediol, which can be converted into either testosterone or estrogen; and androsterone, which is a weak androgen that is produced in the body as a metabolite of testosterone.

It's worth noting that androstenes are sometimes referred to as "pheromones" because they have been found to play a role in chemical communication between individuals of the same species. However, this use of the term "pheromone" is controversial and not universally accepted, as it has been difficult to demonstrate conclusively that humans communicate using chemical signals in the same way that many other animals do.

Hematologic pregnancy complications refer to disorders related to the blood and blood-forming tissues that occur during pregnancy. These complications can have serious consequences for both the mother and the fetus if not properly managed. Some common hematologic pregnancy complications include:

1. Anemia: A condition characterized by a decrease in the number of red blood cells or hemoglobin in the blood, which can lead to fatigue, weakness, and shortness of breath. Iron-deficiency anemia is the most common type of anemia during pregnancy.
2. Thrombocytopenia: A condition characterized by a decrease in the number of platelets (cells that help blood clot) in the blood. Mild thrombocytopenia is relatively common during pregnancy, but severe thrombocytopenia can increase the risk of bleeding during delivery.
3. Gestational thrombotic thrombocytopenic purpura (GTTP): A rare but serious disorder that can cause blood clots to form in small blood vessels throughout the body, leading to a decrease in the number of platelets and red blood cells. GTTP can cause serious complications such as stroke, kidney failure, and even death if not promptly diagnosed and treated.
4. Disseminated intravascular coagulation (DIC): A condition characterized by abnormal clotting and bleeding throughout the body. DIC can be triggered by various conditions such as severe infections, pregnancy complications, or cancer.
5. Hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: A serious complication of pregnancy that can cause damage to the liver and lead to bleeding. HELLP syndrome is often associated with preeclampsia, a condition characterized by high blood pressure and damage to organs such as the liver and kidneys.

It's important for pregnant women to receive regular prenatal care to monitor for these and other potential complications, and to seek prompt medical attention if any concerning symptoms arise.

Risk assessment in the medical context refers to the process of identifying, evaluating, and prioritizing risks to patients, healthcare workers, or the community related to healthcare delivery. It involves determining the likelihood and potential impact of adverse events or hazards, such as infectious diseases, medication errors, or medical devices failures, and implementing measures to mitigate or manage those risks. The goal of risk assessment is to promote safe and high-quality care by identifying areas for improvement and taking action to minimize harm.

Protein C deficiency is a genetic disorder that affects the body's ability to control blood clotting. Protein C is a protein in the blood that helps regulate the formation of blood clots. When blood clots form too easily or do not dissolve properly, they can block blood vessels and lead to serious medical conditions such as deep vein thrombosis (DVT) or pulmonary embolism (PE).

People with protein C deficiency have lower than normal levels of this protein in their blood, which can increase their risk of developing abnormal blood clots. The condition is usually inherited and present from birth, but it may not cause any symptoms until later in life, such as during pregnancy, after surgery, or due to other factors that increase the risk of blood clots.

Protein C deficiency can be classified into two types: type I and type II. Type I deficiency is characterized by lower than normal levels of both functional and immunoreactive protein C in the blood. Type II deficiency is characterized by normal or near-normal levels of immunoreactive protein C, but reduced functional activity.

Protein C deficiency can be diagnosed through blood tests that measure the level and function of protein C in the blood. Treatment may include anticoagulant medications to prevent blood clots from forming or dissolve existing ones. Regular monitoring of protein C levels and careful management of risk factors for blood clots are also important parts of managing this condition.

Protein S deficiency is a genetic disorder that affects the body's ability to coagulate blood properly. Protein S is a naturally occurring protein in the blood that helps regulate the clotting process by deactivating clotting factors when they are no longer needed. When Protein S levels are too low, it can lead to an increased risk of abnormal blood clots forming within blood vessels, a condition known as thrombophilia.

There are three types of Protein S deficiency: Type I (quantitative deficiency), Type II (qualitative deficiency), and Type III (dysfunctional protein). These types refer to the amount or function of Protein S in the blood. In Type I, there is a decrease in both free and total Protein S levels. In Type II, there is a decrease in functional Protein S despite normal total Protein S levels. In Type III, there is a decrease in free Protein S with normal total Protein S levels.

Protein S deficiency can be inherited or acquired. Inherited forms of the disorder are caused by genetic mutations and are usually present from birth. Acquired forms of Protein S deficiency can develop later in life due to certain medical conditions, such as liver disease, vitamin K deficiency, or the use of certain medications that affect blood clotting.

Symptoms of Protein S deficiency may include recurrent blood clots, usually in the legs (deep vein thrombosis) or lungs (pulmonary embolism), skin discoloration, pain, and swelling in the affected area. In severe cases, it can lead to complications such as chronic leg ulcers, pulmonary hypertension, or damage to the heart or lungs.

Diagnosis of Protein S deficiency typically involves blood tests to measure Protein S levels and function. Treatment may include anticoagulant medications to prevent blood clots from forming or growing larger. Lifestyle modifications such as regular exercise, maintaining a healthy weight, and avoiding smoking can also help reduce the risk of blood clots in people with Protein S deficiency.

Phlebography is a medical imaging technique used to visualize and assess the veins, particularly in the legs. It involves the injection of a contrast agent into the veins, followed by X-ray imaging to capture the flow of the contrast material through the veins. This allows doctors to identify any abnormalities such as blood clots, blockages, or malformations in the venous system.

There are different types of phlebography, including ascending phlebography (where the contrast agent is injected into a foot vein and travels up the leg) and descending phlebography (where the contrast agent is injected into a vein in the groin or neck and travels down the leg).

Phlebography is an invasive procedure that requires careful preparation and monitoring, and it is typically performed by radiologists or vascular specialists. It has largely been replaced by non-invasive imaging techniques such as ultrasound and CT angiography in many clinical settings.

A bandage is a medical dressing or covering applied to a wound, injury, or sore with the intention of promoting healing or preventing infection. Bandages can be made of a variety of materials such as gauze, cotton, elastic, or adhesive tape and come in different sizes and shapes to accommodate various body parts. They can also have additional features like fasteners, non-slip surfaces, or transparent windows for monitoring the condition of the wound.

Bandages serve several purposes, including:

1. Absorbing drainage or exudate from the wound
2. Protecting the wound from external contaminants and bacteria
3. Securing other medical devices such as catheters or splints in place
4. Reducing swelling or promoting immobilization of the affected area
5. Providing compression to control bleeding or prevent fluid accumulation
6. Relieving pain by reducing pressure on sensitive nerves or structures.

Proper application and care of bandages are essential for effective wound healing and prevention of complications such as infection or delayed recovery.

Levonorgestrel is a synthetic form of the natural hormone progesterone, which is used in various forms of birth control and emergency contraceptives. It works by preventing ovulation (the release of an egg from the ovaries), thickening cervical mucus to make it harder for sperm to reach the egg, and thinning the lining of the uterus to make it less likely for a fertilized egg to implant.

Medically, Levonorgestrel is classified as a progestin and is available in various forms, including oral tablets, intrauterine devices (IUDs), and emergency contraceptive pills. It may also be used to treat endometriosis, irregular menstrual cycles, and heavy menstrual bleeding.

It's important to note that while Levonorgestrel is a highly effective form of birth control when used correctly, it does not protect against sexually transmitted infections (STIs). Therefore, condoms should still be used during sexual activity if there is any risk of STI transmission.

Thiophenes are organic compounds that contain a heterocyclic ring made up of four carbon atoms and one sulfur atom. The structure of thiophene is similar to benzene, with the benzene ring being replaced by a thiophene ring. Thiophenes are aromatic compounds, which means they have a stable, planar ring structure and delocalized electrons.

Thiophenes can be found in various natural sources such as coal tar, crude oil, and some foods like onions and garlic. They also occur in certain medications, dyes, and pesticides. Some thiophene derivatives have been synthesized and studied for their potential therapeutic uses, including anti-inflammatory, antiviral, and antitumor activities.

In the medical field, thiophenes are used in some pharmaceuticals as building blocks to create drugs with various therapeutic effects. For example, tipepidine, a cough suppressant, contains a thiophene ring. Additionally, some anesthetics and antipsychotic medications also contain thiophene moieties.

It is important to note that while thiophenes themselves are not typically considered medical terms, they play a role in the chemistry of various pharmaceuticals and other medical-related compounds.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

Thrombosis is the formation of a blood clot (thrombus) inside a blood vessel, obstructing the flow of blood through the circulatory system. When a clot forms in an artery, it can cut off the supply of oxygen and nutrients to the tissues served by that artery, leading to damage or tissue death. If a thrombus forms in the heart, it can cause a heart attack. If a thrombus breaks off and travels through the bloodstream, it can lodge in a smaller vessel, causing blockage and potentially leading to damage in the organ that the vessel supplies. This is known as an embolism.

Thrombosis can occur due to various factors such as injury to the blood vessel wall, abnormalities in blood flow, or changes in the composition of the blood. Certain medical conditions, medications, and lifestyle factors can increase the risk of thrombosis. Treatment typically involves anticoagulant or thrombolytic therapy to dissolve or prevent further growth of the clot, as well as addressing any underlying causes.

Beta-alanine is a non-essential amino acid, which means that it is not required in the diet because the body can produce it from other amino acids. It is produced in the liver and is also found in some foods such as meat, poultry, and fish.

Beta-alanine plays a role in the production of carnosine, a dipeptide molecule that helps to regulate muscle pH and improve muscle function during high-intensity exercise. When muscles contract during intense exercise, they produce hydrogen ions, which can cause the muscle pH to decrease (become more acidic), leading to fatigue and reduced muscle function. Carnosine acts as a buffer against this acidity, helping to maintain optimal muscle pH levels and improve performance during high-intensity exercise.

Beta-alanine supplements have been shown to increase carnosine levels in muscles, which may lead to improved athletic performance, particularly in activities that require short bursts of intense effort, such as weightlifting or sprinting. However, more research is needed to fully understand the effects and potential benefits of beta-alanine supplementation.

It's important to note that while beta-alanine supplements are generally considered safe for most people, they can cause a tingling sensation in the skin (paresthesia) when taken in high doses. This is a harmless side effect and typically subsides within an hour or so of taking the supplement.

I'm sorry for any confusion, but "Austria" is not a medical term or concept. It is a country located in central Europe, known officially as the Republic of Austria. It is not a medical condition, treatment, or related term. If you have any questions about a medical issue, I would be happy to try to help answer those for you!

Factor Xa is a serine protease that plays a crucial role in the coagulation cascade, which is a series of reactions that lead to the formation of a blood clot. It is one of the activated forms of Factor X, a pro-protein that is converted to Factor Xa through the action of other enzymes in the coagulation cascade.

Factor Xa functions as a key component of the prothrombinase complex, which also includes calcium ions, phospholipids, and activated Factor V (also known as Activated Protein C or APC). This complex is responsible for converting prothrombin to thrombin, which then converts fibrinogen to fibrin, forming a stable clot.

Inhibitors of Factor Xa are used as anticoagulants in the prevention and treatment of thromboembolic disorders such as deep vein thrombosis and pulmonary embolism. These drugs work by selectively inhibiting Factor Xa, thereby preventing the formation of the prothrombinase complex and reducing the risk of clot formation.

Norpregnenes are a class of steroids that are produced by the metabolism of progesterone and other pregnanes. They are characterized by the absence of a double bond between carbons 4 and 5, and the presence of a ketone group at carbon 3. Some examples of norpregnenes include dehydroepiandrosterone (DHEA), androstenedione, and pregnenolone. These steroids are important intermediates in the biosynthesis of various hormones, including cortisol, aldosterone, androgens, and estrogens. They play a role in various physiological processes such as sexual development, immune function, and stress response.

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

Oral contraceptives, also known as "birth control pills," are synthetic hormonal medications that are taken by mouth to prevent pregnancy. They typically contain a combination of synthetic versions of the female hormones estrogen and progesterone, which work together to inhibit ovulation (the release of an egg from the ovaries), thicken cervical mucus (making it harder for sperm to reach the egg), and thin the lining of the uterus (making it less likely that a fertilized egg will implant).

There are several different types of oral contraceptives, including combination pills, progestin-only pills, and extended-cycle pills. Combination pills contain both estrogen and progestin, while progestin-only pills contain only progestin. Extended-cycle pills are a type of combination pill that are taken for 12 weeks followed by one week of placebo pills, which can help reduce the frequency of menstrual periods.

It's important to note that oral contraceptives do not protect against sexually transmitted infections (STIs), so it's still important to use barrier methods like condoms if you are at risk for STIs. Additionally, oral contraceptives can have side effects and may not be suitable for everyone, so it's important to talk to your healthcare provider about the potential risks and benefits before starting to take them.

Practice guidelines, also known as clinical practice guidelines, are systematically developed statements that aim to assist healthcare professionals and patients in making informed decisions about appropriate health care for specific clinical circumstances. They are based on a thorough evaluation of the available scientific evidence, consensus of expert opinion, and consideration of patient preferences. Practice guidelines can cover a wide range of topics, including diagnosis, management, prevention, and treatment options for various medical conditions. They are intended to improve the quality and consistency of care, reduce unnecessary variations in practice, and promote evidence-based medicine. However, they should not replace clinical judgment or individualized patient care.

Acenocoumarol is an anticoagulant medication that is used to prevent and treat blood clots. It works by inhibiting the formation of vitamin K-dependent clotting factors, which are necessary for normal blood coagulation. This results in a prolonged bleeding time and reduced risk of blood clots.

Acenocoumarol is a coumarin derivative and is available under various brand names, including Sintrom and Nicoumalone. It is typically administered orally in the form of tablets and its effects are monitored through regular blood tests to ensure that the dosage is appropriate and that the risk of bleeding complications is minimized.

Common side effects of acenocoumarol include easy bruising, nosebleeds, and skin rashes. It may also interact with a variety of other medications, including antibiotics, antifungals, and certain herbal supplements, so it is important to inform your healthcare provider of all medications and supplements you are taking before starting acenocoumarol therapy.

It is important to note that acenocoumarol has a narrow therapeutic index, meaning that the difference between an effective dose and a toxic dose is relatively small. Therefore, it is essential to follow your healthcare provider's instructions carefully when taking this medication and to have regular blood tests to monitor its effects on your coagulation status.

In the context of medicine, risk is the probability or likelihood of an adverse health effect or the occurrence of a negative event related to treatment or exposure to certain hazards. It is usually expressed as a ratio or percentage and can be influenced by various factors such as age, gender, lifestyle, genetics, and environmental conditions. Risk assessment involves identifying, quantifying, and prioritizing risks to make informed decisions about prevention, mitigation, or treatment strategies.

Cardiovascular complications in pregnancy refer to conditions that affect the heart and blood vessels, which can arise during pregnancy, childbirth, or after delivery. These complications can be pre-existing or new-onset and can range from mild to severe, potentially threatening the life of both the mother and the fetus. Some examples of cardiovascular complications in pregnancy include:

1. Hypertension disorders: This includes chronic hypertension (high blood pressure before pregnancy), gestational hypertension (high blood pressure that develops after 20 weeks of pregnancy), and preeclampsia/eclampsia (a pregnancy-specific disorder characterized by high blood pressure, proteinuria, and potential organ damage).

2. Cardiomyopathy: A condition in which the heart muscle becomes weakened, leading to an enlarged heart and reduced pumping efficiency. Peripartum cardiomyopathy is a specific type that occurs during pregnancy or in the months following delivery.

3. Arrhythmias: Irregularities in the heart's rhythm, such as tachycardia (rapid heartbeat) or bradycardia (slow heartbeat), can occur during pregnancy and may require medical intervention.

4. Valvular heart disease: Pre-existing valve disorders, like mitral stenosis or aortic insufficiency, can worsen during pregnancy due to increased blood volume and cardiac output. Additionally, new valve issues might develop during pregnancy.

5. Venous thromboembolism (VTE): Pregnancy increases the risk of developing blood clots in the veins, particularly deep vein thrombosis (DVT) or pulmonary embolism (PE).

6. Ischemic heart disease: Although rare, coronary artery disease and acute coronary syndrome can occur during pregnancy, especially in women with risk factors such as obesity, diabetes, or smoking history.

7. Heart failure: Severe cardiac dysfunction leading to fluid accumulation, shortness of breath, and reduced exercise tolerance may develop due to any of the above conditions or other underlying heart diseases.

Early recognition, monitoring, and appropriate management of these cardiovascular complications in pregnancy are crucial for maternal and fetal well-being.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Oral contraceptives, also known as "birth control pills," are medications taken by mouth to prevent pregnancy. They contain synthetic hormones that mimic the effects of natural hormones estrogen and progesterone in a woman's body, thereby preventing ovulation, fertilization, or implantation of a fertilized egg in the uterus.

There are two main types of oral contraceptives: combined pills, which contain both estrogen and progestin, and mini-pills, which contain only progestin. Combined pills work by preventing ovulation, thickening cervical mucus to make it harder for sperm to reach the egg, and thinning the lining of the uterus to make it less likely for a fertilized egg to implant. Mini-pills work mainly by thickening cervical mucus and changing the lining of the uterus.

Oral contraceptives are highly effective when used correctly, but they do not protect against sexually transmitted infections (STIs). It is important to use them consistently and as directed by a healthcare provider. Side effects may include nausea, breast tenderness, headaches, mood changes, and irregular menstrual bleeding. In rare cases, oral contraceptives may increase the risk of serious health problems such as blood clots, stroke, or liver tumors. However, for most women, the benefits of using oral contraceptives outweigh the risks.

A cohort study is a type of observational study in which a group of individuals who share a common characteristic or exposure are followed up over time to determine the incidence of a specific outcome or outcomes. The cohort, or group, is defined based on the exposure status (e.g., exposed vs. unexposed) and then monitored prospectively to assess for the development of new health events or conditions.

Cohort studies can be either prospective or retrospective in design. In a prospective cohort study, participants are enrolled and followed forward in time from the beginning of the study. In contrast, in a retrospective cohort study, researchers identify a cohort that has already been assembled through medical records, insurance claims, or other sources and then look back in time to assess exposure status and health outcomes.

Cohort studies are useful for establishing causality between an exposure and an outcome because they allow researchers to observe the temporal relationship between the two. They can also provide information on the incidence of a disease or condition in different populations, which can be used to inform public health policy and interventions. However, cohort studies can be expensive and time-consuming to conduct, and they may be subject to bias if participants are not representative of the population or if there is loss to follow-up.

Compression bandages are medical devices used to apply pressure on a part of the body, typically on limbs such as arms or legs. They are often used in the treatment of venous disorders, lymphatic disorders, and wounds, including venous ulcers, leg edema, and chronic swelling. The compression helps to promote better blood flow, reduce swelling, and aid in the healing process by helping to prevent fluid buildup in the tissues. They are usually made from elastic materials that allow for adjustable levels of compression and can be wrapped around the affected area in a specific manner to ensure proper fit and effectiveness. It is important to receive proper instruction on the application and removal of compression bandages to ensure they are used safely and effectively.

Blood coagulation, also known as blood clotting, is a complex process that occurs in the body to prevent excessive bleeding when a blood vessel is damaged. This process involves several different proteins and chemical reactions that ultimately lead to the formation of a clot.

The coagulation cascade is initiated when blood comes into contact with tissue factor, which is exposed after damage to the blood vessel wall. This triggers a series of enzymatic reactions that activate clotting factors, leading to the formation of a fibrin clot. Fibrin is a protein that forms a mesh-like structure that traps platelets and red blood cells to form a stable clot.

Once the bleeding has stopped, the coagulation process is regulated and inhibited to prevent excessive clotting. The fibrinolytic system degrades the clot over time, allowing for the restoration of normal blood flow.

Abnormalities in the blood coagulation process can lead to bleeding disorders or thrombotic disorders such as deep vein thrombosis and pulmonary embolism.

Pyridones are a class of organic compounds that contain a pyridone ring, which is a heterocyclic ring consisting of a six-membered ring with five carbon atoms and one nitrogen atom, with one oxygen atom attached to the nitrogen atom by a double bond. Pyridones can be found in various natural sources, including plants and microorganisms, and they also have important applications in the pharmaceutical industry as building blocks for drug design and synthesis. Some drugs that contain pyridone rings include antihistamines, anti-inflammatory agents, and antiviral agents.

Arthroplasty, replacement, knee is a surgical procedure where the damaged or diseased joint surface of the knee is removed and replaced with an artificial joint or prosthesis. The procedure involves resurfacing the worn-out ends of the femur (thigh bone) and tibia (shin bone) with metal components, and the back of the kneecap with a plastic button. This surgery is usually performed to relieve pain and restore function in patients with severe knee osteoarthritis, rheumatoid arthritis, or traumatic injuries that have damaged the joint beyond repair. The goal of knee replacement surgery is to improve mobility, reduce pain, and enhance the quality of life for the patient.

Oral administration is a route of giving medications or other substances by mouth. This can be in the form of tablets, capsules, liquids, pastes, or other forms that can be swallowed. Once ingested, the substance is absorbed through the gastrointestinal tract and enters the bloodstream to reach its intended target site in the body. Oral administration is a common and convenient route of medication delivery, but it may not be appropriate for all substances or in certain situations, such as when rapid onset of action is required or when the patient has difficulty swallowing.

Subcutaneous injection is a route of administration where a medication or vaccine is delivered into the subcutaneous tissue, which lies between the skin and the muscle. This layer contains small blood vessels, nerves, and connective tissues that help to absorb the medication slowly and steadily over a period of time. Subcutaneous injections are typically administered using a short needle, at an angle of 45-90 degrees, and the dose is injected slowly to minimize discomfort and ensure proper absorption. Common sites for subcutaneous injections include the abdomen, thigh, or upper arm. Examples of medications that may be given via subcutaneous injection include insulin, heparin, and some vaccines.

Follow-up studies are a type of longitudinal research that involve repeated observations or measurements of the same variables over a period of time, in order to understand their long-term effects or outcomes. In medical context, follow-up studies are often used to evaluate the safety and efficacy of medical treatments, interventions, or procedures.

In a typical follow-up study, a group of individuals (called a cohort) who have received a particular treatment or intervention are identified and then followed over time through periodic assessments or data collection. The data collected may include information on clinical outcomes, adverse events, changes in symptoms or functional status, and other relevant measures.

The results of follow-up studies can provide important insights into the long-term benefits and risks of medical interventions, as well as help to identify factors that may influence treatment effectiveness or patient outcomes. However, it is important to note that follow-up studies can be subject to various biases and limitations, such as loss to follow-up, recall bias, and changes in clinical practice over time, which must be carefully considered when interpreting the results.

Immobilization is a medical term that refers to the restriction of normal mobility or motion of a body part, usually to promote healing and prevent further injury. This is often achieved through the use of devices such as casts, splints, braces, slings, or traction. The goal of immobilization is to keep the injured area in a fixed position so that it can heal properly without additional damage. It may be used for various medical conditions, including fractures, dislocations, sprains, strains, and soft tissue injuries. Immobilization helps reduce pain, minimize swelling, and protect the injured site from movement that could worsen the injury or impair healing.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Hospitalization is the process of admitting a patient to a hospital for the purpose of receiving medical treatment, surgery, or other health care services. It involves staying in the hospital as an inpatient, typically under the care of doctors, nurses, and other healthcare professionals. The length of stay can vary depending on the individual's medical condition and the type of treatment required. Hospitalization may be necessary for a variety of reasons, such as to receive intensive care, to undergo diagnostic tests or procedures, to recover from surgery, or to manage chronic illnesses or injuries.

A case-control study is an observational research design used to identify risk factors or causes of a disease or health outcome. In this type of study, individuals with the disease or condition (cases) are compared with similar individuals who do not have the disease or condition (controls). The exposure history or other characteristics of interest are then compared between the two groups to determine if there is an association between the exposure and the disease.

Case-control studies are often used when it is not feasible or ethical to conduct a randomized controlled trial, as they can provide valuable insights into potential causes of diseases or health outcomes in a relatively short period of time and at a lower cost than other study designs. However, because case-control studies rely on retrospective data collection, they are subject to biases such as recall bias and selection bias, which can affect the validity of the results. Therefore, it is important to carefully design and conduct case-control studies to minimize these potential sources of bias.

Protein C is a vitamin K-dependent protease that functions as an important regulator of coagulation and inflammation. It is a plasma protein produced in the liver that, when activated, degrades clotting factors Va and VIIIa to limit thrombus formation and prevent excessive blood clotting. Protein C also has anti-inflammatory properties by inhibiting the release of pro-inflammatory cytokines and reducing endothelial cell activation. Inherited or acquired deficiencies in Protein C can lead to an increased risk of thrombosis, a condition characterized by abnormal blood clot formation within blood vessels.

Antithrombins are substances that prevent the formation or promote the dissolution of blood clots (thrombi). They include:

1. Anticoagulants: These are medications that reduce the ability of the blood to clot. Examples include heparin, warfarin, and direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran.
2. Thrombolytic agents: These are medications that break down existing blood clots. Examples include alteplase, reteplase, and tenecteplase.
3. Fibrinolytics: These are a type of thrombolytic agent that specifically target fibrin, a protein involved in the formation of blood clots.
4. Natural anticoagulants: These are substances produced by the body to regulate blood clotting. Examples include antithrombin III, protein C, and protein S.

Antithrombins are used in the prevention and treatment of various thromboembolic disorders, such as deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction (heart attack). It is important to note that while antithrombins can help prevent or dissolve blood clots, they also increase the risk of bleeding, so their use must be carefully monitored.

Hip arthroplasty, also known as hip replacement surgery, is a medical procedure where the damaged or diseased joint surfaces of the hip are removed and replaced with artificial components. These components typically include a metal or ceramic ball that replaces the head of the femur (thigh bone), and a polyethylene or ceramic socket that replaces the acetabulum (hip socket) in the pelvis.

The goal of hip arthroplasty is to relieve pain, improve joint mobility, and restore function to the hip joint. This procedure is commonly performed in patients with advanced osteoarthritis, rheumatoid arthritis, hip fractures, or other conditions that cause significant damage to the hip joint.

There are several types of hip replacement surgeries, including traditional total hip arthroplasty, partial (hemi) hip arthroplasty, and resurfacing hip arthroplasty. The choice of procedure depends on various factors, such as the patient's age, activity level, overall health, and the extent of joint damage.

After surgery, patients typically require rehabilitation to regain strength, mobility, and function in the affected hip. With proper care and follow-up, most patients can expect significant pain relief and improved quality of life following hip arthroplasty.

Aerospace medicine is a branch of medicine that deals with the health and safety of pilots, astronauts, and passengers during space travel or aircraft flight. It involves studying the effects of various factors such as altitude, weightlessness, radiation, noise, vibration, and temperature extremes on the human body, and developing measures to prevent or mitigate any adverse effects.

Aerospace medicine also encompasses the diagnosis and treatment of medical conditions that occur during space travel or aircraft flight, as well as the development of medical standards and guidelines for pilot and astronaut selection, training, and fitness for duty. Additionally, it includes research into the physiological and psychological challenges of long-duration space missions and the development of countermeasures to maintain crew health and performance during such missions.

"Gravity suits" is not a recognized medical term. However, in the context of space medicine and space travel, gravity suits, also known as g-suits or anti-G suits, are specialized garments worn by pilots and astronauts to prevent or reduce the negative effects of high gravitational forces (G-forces) on their bodies during high-speed maneuvers or while re-entering the Earth's atmosphere.

These suits work by applying pressure to specific areas of the body, typically around the lower abdomen and legs, to prevent the pooling of blood in those areas due to the increased G-forces. This helps maintain adequate blood flow to the brain and other vital organs, reducing the risk of loss of consciousness (G-induced Loss of Consciousness or G-LOC) and other symptoms associated with high G-forces such as blackouts, vision impairment, and disorientation.

It's important to note that gravity suits are not used as a medical treatment for any specific condition but rather as a protective measure during space travel and high-performance aviation.

'Hospital Bed Capacity, 3

The double-blind method is a study design commonly used in research, including clinical trials, to minimize bias and ensure the objectivity of results. In this approach, both the participants and the researchers are unaware of which group the participants are assigned to, whether it be the experimental group or the control group. This means that neither the participants nor the researchers know who is receiving a particular treatment or placebo, thus reducing the potential for bias in the evaluation of outcomes. The assignment of participants to groups is typically done by a third party not involved in the study, and the codes are only revealed after all data have been collected and analyzed.

Blood coagulation factors, also known as clotting factors, are a group of proteins that play a crucial role in the blood coagulation process. They are essential for maintaining hemostasis, which is the body's ability to stop bleeding after injury.

There are 13 known blood coagulation factors, and they are designated by Roman numerals I through XIII. These factors are produced in the liver and are normally present in an inactive form in the blood. When there is an injury to a blood vessel, the coagulation process is initiated, leading to the activation of these factors in a specific order.

The coagulation cascade involves two pathways: the intrinsic and extrinsic pathways. The intrinsic pathway is activated when there is damage to the blood vessel itself, while the extrinsic pathway is activated by tissue factor released from damaged tissues. Both pathways converge at the common pathway, leading to the formation of a fibrin clot.

Blood coagulation factors work together in a complex series of reactions that involve activation, binding, and proteolysis. When one factor is activated, it activates the next factor in the cascade, and so on. This process continues until a stable fibrin clot is formed.

Deficiencies or abnormalities in blood coagulation factors can lead to bleeding disorders such as hemophilia or thrombosis. Hemophilia is a genetic disorder that affects one or more of the coagulation factors, leading to excessive bleeding and difficulty forming clots. Thrombosis, on the other hand, occurs when there is an abnormal formation of blood clots in the blood vessels, which can lead to serious complications such as stroke or pulmonary embolism.

Orthopedic procedures are surgical or nonsurgical methods used to treat musculoskeletal conditions, including injuries, deformities, or diseases of the bones, joints, muscles, ligaments, and tendons. These procedures can range from simple splinting or casting to complex surgeries such as joint replacements, spinal fusions, or osteotomies (cutting and repositioning bones). The primary goal of orthopedic procedures is to restore function, reduce pain, and improve the quality of life for patients.

Factor VIII is a protein in the blood that is essential for normal blood clotting. It is also known as antihemophilic factor (AHF). Deficiency or dysfunction of this protein results in hemophilia A, a genetic disorder characterized by prolonged bleeding and easy bruising. Factor VIII works together with other proteins to help form a clot and stop bleeding at the site of an injury. It acts as a cofactor for another clotting factor, IX, in the so-called intrinsic pathway of blood coagulation. Intravenous infusions of Factor VIII concentrate are used to treat and prevent bleeding episodes in people with hemophilia A.

Guideline adherence, in the context of medicine, refers to the extent to which healthcare professionals follow established clinical practice guidelines or recommendations in their daily practice. These guidelines are systematically developed statements designed to assist practitioners and patient decisions about appropriate health care for specific clinical circumstances. Adherence to evidence-based guidelines can help improve the quality of care, reduce unnecessary variations in practice, and promote optimal patient outcomes. Factors that may influence guideline adherence include clinician awareness, familiarity, agreement, self-efficacy, outcome expectancy, and the complexity of the recommendation.

Antithrombin III (ATIII) deficiency is a genetic disorder that affects the body's ability to regulate blood clotting. ATIII is a protein produced in the liver that inhibits the activity of thrombin and other coagulation factors, preventing excessive clot formation.

People with ATIII deficiency have lower than normal levels of this protein, which can lead to an increased risk of developing abnormal blood clots (thrombosis) in veins, particularly deep vein thrombosis (DVT) and pulmonary embolism (PE). These clots can cause serious complications, including damage to the affected veins, organ damage, and even death.

ATIII deficiency can be classified into two types: type I and type II. Type I is characterized by a quantitative decrease in ATIII levels, while type II is characterized by a qualitative defect that results in reduced functional activity of the protein.

The condition is usually inherited in an autosomal dominant manner, meaning that a person has a 50% chance of inheriting the gene mutation from an affected parent. However, some cases may occur spontaneously due to new mutations in the ATIII gene. Treatment for ATIII deficiency typically involves anticoagulation therapy with medications such as heparin or warfarin to prevent blood clots from forming.

Partial Thromboplastin Time (PTT) is a medical laboratory test that measures the time it takes for blood to clot. It's more specifically a measure of the intrinsic and common pathways of the coagulation cascade, which are the series of chemical reactions that lead to the formation of a clot.

The test involves adding a partial thromboplastin reagent (an activator of the intrinsic pathway) and calcium to plasma, and then measuring the time it takes for a fibrin clot to form. This is compared to a control sample, and the ratio of the two times is calculated.

The PTT test is often used to help diagnose bleeding disorders or abnormal blood clotting, such as hemophilia or disseminated intravascular coagulation (DIC). It can also be used to monitor the effectiveness of anticoagulant therapy, such as heparin. Prolonged PTT results may indicate a bleeding disorder or an increased risk of bleeding, while shortened PTT results may indicate a hypercoagulable state and an increased risk of thrombosis.

A randomized controlled trial (RCT) is a type of clinical study in which participants are randomly assigned to receive either the experimental intervention or the control condition, which may be a standard of care, placebo, or no treatment. The goal of an RCT is to minimize bias and ensure that the results are due to the intervention being tested rather than other factors. This design allows for a comparison between the two groups to determine if there is a significant difference in outcomes. RCTs are often considered the gold standard for evaluating the safety and efficacy of medical interventions, as they provide a high level of evidence for causal relationships between the intervention and health outcomes.

Polysaccharides are complex carbohydrates consisting of long chains of monosaccharide units (simple sugars) bonded together by glycosidic linkages. They can be classified based on the type of monosaccharides and the nature of the bonds that connect them.

Polysaccharides have various functions in living organisms. For example, starch and glycogen serve as energy storage molecules in plants and animals, respectively. Cellulose provides structural support in plants, while chitin is a key component of fungal cell walls and arthropod exoskeletons.

Some polysaccharides also have important roles in the human body, such as being part of the extracellular matrix (e.g., hyaluronic acid) or acting as blood group antigens (e.g., ABO blood group substances).

A "Drug Administration Schedule" refers to the plan for when and how a medication should be given to a patient. It includes details such as the dose, frequency (how often it should be taken), route (how it should be administered, such as orally, intravenously, etc.), and duration (how long it should be taken) of the medication. This schedule is often created and prescribed by healthcare professionals, such as doctors or pharmacists, to ensure that the medication is taken safely and effectively. It may also include instructions for missed doses or changes in the dosage.

Premedication is the administration of medication before a medical procedure or surgery to prevent or manage pain, reduce anxiety, minimize side effects of anesthesia, or treat existing medical conditions. The goal of premedication is to improve the safety and outcomes of the medical procedure by preparing the patient's body in advance. Common examples of premedication include administering antibiotics before surgery to prevent infection, giving sedatives to help patients relax before a procedure, or providing medication to control acid reflux during surgery.

I'm sorry for any confusion, but "Morpholines" is not a medical term. It is a chemical term that refers to a class of heterocyclic organic compounds containing one nitrogen atom and one oxygen atom in the ring. They are widely used as intermediates in the synthesis of various pharmaceuticals, agrochemicals, and dyes. If you have any questions about a medical issue or term, I'd be happy to try to help answer those for you!

An inpatient, in medical terms, refers to a person who has been admitted to a hospital or other healthcare facility for the purpose of receiving medical treatment and who is expected to remain there for at least one night. Inpatients are typically cared for by a team of healthcare professionals, including doctors, nurses, and therapists, and may receive various treatments, such as medications, surgeries, or rehabilitation services.

Inpatient care is generally recommended for patients who require close monitoring, frequent assessments, or intensive medical interventions that cannot be provided in an outpatient setting. The length of stay for inpatients can vary widely depending on the nature and severity of their condition, as well as their individual treatment plan.

Factor V deficiency is a rare bleeding disorder that is caused by a mutation in the gene that produces coagulation factor V, a protein involved in the clotting process. This condition can lead to excessive bleeding following injury or surgery, and may also cause menorrhagia (heavy menstrual periods) in women.

Factor V deficiency is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene (one from each parent) in order to develop the condition. People who inherit only one copy of the mutated gene are carriers and may have a milder form of the disorder or no symptoms at all.

Treatment for factor V deficiency typically involves replacement therapy with fresh frozen plasma or clotting factor concentrates, which can help to reduce bleeding episodes and prevent complications. In some cases, medications such as desmopressin or antifibrinolytics may also be used to manage the condition.

Puerperal disorders are a group of medical conditions that can affect women during the period following childbirth, also known as the puerperium. The puerperium typically lasts for six to eight weeks after delivery. These disorders can be complications of childbirth or postpartum infections and include:

1. Puerperal fever: This is a febrile illness that occurs during the puerperium, usually caused by a bacterial infection. The most common causative organisms are group A streptococcus, Staphylococcus aureus, and Escherichia coli.

2. Puerperal sepsis: This is a severe form of puerperal fever characterized by the presence of bacteria in the blood (bacteremia) and widespread inflammation throughout the body. It can lead to organ failure and even death if not treated promptly with antibiotics.

3. Puerperal endometritis: This is an infection of the lining of the uterus (endometrium) that occurs during the puerperium. Symptoms may include fever, abdominal pain, and foul-smelling vaginal discharge.

4. Puerperal mastitis: This is an inflammation of the breast tissue that can occur during lactation, often caused by a bacterial infection. It is more common in women who are breastfeeding but can also occur in non-lactating women.

5. Puerperal psychosis: This is a rare but serious mental health disorder that can occur after childbirth. It is characterized by symptoms such as delusions, hallucinations, and disorganized thinking.

6. Puerperal thromboembolism: This is a blood clot that forms during the puerperium, usually in the deep veins of the legs (deep vein thrombosis) or in the lungs (pulmonary embolism). It can be a serious complication of childbirth and requires prompt medical attention.

Overall, puerperal disorders are a significant cause of maternal morbidity and mortality worldwide, particularly in low-income countries where access to healthcare is limited. Prompt diagnosis and treatment are essential for improving outcomes and reducing the risk of long-term complications.

Blood coagulation tests, also known as coagulation studies or clotting tests, are a series of medical tests used to evaluate the blood's ability to clot. These tests measure the functioning of various clotting factors and regulatory proteins involved in the coagulation cascade, which is a complex process that leads to the formation of a blood clot to prevent excessive bleeding.

The most commonly performed coagulation tests include:

1. Prothrombin Time (PT): Measures the time it takes for a sample of plasma to clot after the addition of calcium and tissue factor, which activates the extrinsic pathway of coagulation. The PT is reported in seconds and can be converted to an International Normalized Ratio (INR) to monitor anticoagulant therapy.
2. Activated Partial Thromboplastin Time (aPTT): Measures the time it takes for a sample of plasma to clot after the addition of calcium, phospholipid, and a contact activator, which activates the intrinsic pathway of coagulation. The aPTT is reported in seconds and is used to monitor heparin therapy.
3. Thrombin Time (TT): Measures the time it takes for a sample of plasma to clot after the addition of thrombin, which directly converts fibrinogen to fibrin. The TT is reported in seconds and can be used to detect the presence of fibrin degradation products or abnormalities in fibrinogen function.
4. Fibrinogen Level: Measures the amount of fibrinogen, a protein involved in clot formation, present in the blood. The level is reported in grams per liter (g/L) and can be used to assess bleeding risk or the effectiveness of fibrinogen replacement therapy.
5. D-dimer Level: Measures the amount of D-dimer, a protein fragment produced during the breakdown of a blood clot, present in the blood. The level is reported in micrograms per milliliter (µg/mL) and can be used to diagnose or exclude venous thromboembolism (VTE), such as deep vein thrombosis (DVT) or pulmonary embolism (PE).

These tests are important for the diagnosis, management, and monitoring of various bleeding and clotting disorders. They can help identify the underlying cause of abnormal bleeding or clotting, guide appropriate treatment decisions, and monitor the effectiveness of therapy. It is essential to interpret these test results in conjunction with a patient's clinical presentation and medical history.

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies in the blood. These antibodies are directed against phospholipids, a type of fat molecule found in cell membranes and plasma lipoproteins. The presence of these antibodies can lead to abnormal blood clotting, which can cause serious complications such as stroke, heart attack, deep vein thrombosis, and pulmonary embolism.

APS can occur either on its own (primary APS) or in conjunction with other autoimmune disorders, such as systemic lupus erythematosus (secondary APS). The exact cause of APS is not fully understood, but it is believed to involve a combination of genetic and environmental factors.

Symptoms of APS can vary widely depending on the location and severity of the blood clots. They may include:

* Recurrent miscarriages or stillbirths
* Blood clots in the legs, lungs, or other parts of the body
* Skin ulcers or lesions
* Headaches, seizures, or stroke-like symptoms
* Kidney problems
* Heart valve abnormalities

Diagnosis of APS typically involves blood tests to detect the presence of antiphospholipid antibodies. Treatment may include medications to prevent blood clots, such as anticoagulants and antiplatelet agents, as well as management of any underlying autoimmune disorders.

Antiphospholipid antibodies are a type of autoantibody that targets and binds to certain proteins found in the blood that attach to phospholipids (a type of fat molecule). These antibodies are associated with an increased risk of developing antiphospholipid syndrome, a disorder characterized by abnormal blood clotting.

There are several types of antiphospholipid antibodies, including:

1. Lupus anticoagulant: This type of antiphospholipid antibody can interfere with blood clotting tests and may increase the risk of thrombosis (blood clots) in both arteries and veins.
2. Anticardiolipin antibodies: These antibodies target a specific phospholipid called cardiolipin, which is found in the inner membrane of mitochondria. High levels of anticardiolipin antibodies are associated with an increased risk of thrombosis and pregnancy complications such as recurrent miscarriage.
3. Anti-β2 glycoprotein I antibodies: These antibodies target a protein called β2 glycoprotein I, which binds to negatively charged phospholipids on the surface of cells. High levels of anti-β2 glycoprotein I antibodies are associated with an increased risk of thrombosis and pregnancy complications.

The exact mechanism by which antiphospholipid antibodies cause blood clotting is not fully understood, but it is thought to involve the activation of platelets, the inhibition of natural anticoagulants, and the promotion of inflammation. Antiphospholipid syndrome can be treated with medications that thin the blood or prevent clots from forming, such as aspirin, warfarin, or heparin.

"Age factors" refer to the effects, changes, or differences that age can have on various aspects of health, disease, and medical care. These factors can encompass a wide range of issues, including:

1. Physiological changes: As people age, their bodies undergo numerous physical changes that can affect how they respond to medications, illnesses, and medical procedures. For example, older adults may be more sensitive to certain drugs or have weaker immune systems, making them more susceptible to infections.
2. Chronic conditions: Age is a significant risk factor for many chronic diseases, such as heart disease, diabetes, cancer, and arthritis. As a result, age-related medical issues are common and can impact treatment decisions and outcomes.
3. Cognitive decline: Aging can also lead to cognitive changes, including memory loss and decreased decision-making abilities. These changes can affect a person's ability to understand and comply with medical instructions, leading to potential complications in their care.
4. Functional limitations: Older adults may experience physical limitations that impact their mobility, strength, and balance, increasing the risk of falls and other injuries. These limitations can also make it more challenging for them to perform daily activities, such as bathing, dressing, or cooking.
5. Social determinants: Age-related factors, such as social isolation, poverty, and lack of access to transportation, can impact a person's ability to obtain necessary medical care and affect their overall health outcomes.

Understanding age factors is critical for healthcare providers to deliver high-quality, patient-centered care that addresses the unique needs and challenges of older adults. By taking these factors into account, healthcare providers can develop personalized treatment plans that consider a person's age, physical condition, cognitive abilities, and social circumstances.

Benzimidazoles are a class of heterocyclic compounds containing a benzene fused to a imidazole ring. They have a wide range of pharmacological activities and are used in the treatment of various diseases. Some of the benzimidazoles are used as antiparasitics, such as albendazole and mebendazole, which are effective against a variety of worm infestations. Other benzimidazoles have antifungal properties, such as thiabendazole and fuberidazole, and are used to treat fungal infections. Additionally, some benzimidazoles have been found to have anti-cancer properties and are being investigated for their potential use in cancer therapy.

Aspirin is the common name for acetylsalicylic acid, which is a medication used to relieve pain, reduce inflammation, and lower fever. It works by inhibiting the activity of an enzyme called cyclooxygenase (COX), which is involved in the production of prostaglandins, hormone-like substances that cause inflammation and pain. Aspirin also has an antiplatelet effect, which means it can help prevent blood clots from forming. This makes it useful for preventing heart attacks and strokes.

Aspirin is available over-the-counter in various forms, including tablets, capsules, and chewable tablets. It is also available in prescription strengths for certain medical conditions. As with any medication, aspirin should be taken as directed by a healthcare provider, and its use should be avoided in children and teenagers with viral infections due to the risk of Reye's syndrome, a rare but serious condition that can affect the liver and brain.

Oral hormonal contraceptives, also known as "birth control pills," are a type of medication that contains synthetic hormones (estrogen and/or progestin) that are taken by mouth to prevent pregnancy. They work by preventing ovulation (the release of an egg from the ovaries), thickening cervical mucus to make it harder for sperm to reach the egg, and thinning the lining of the uterus to make it less likely for a fertilized egg to implant.

There are several different types of oral hormonal contraceptives, including combined pills that contain both estrogen and progestin, and mini-pills that only contain progestin. These medications are usually taken daily for 21 days, followed by a seven-day break during which menstruation occurs. Some newer formulations may be taken continuously with no break.

It's important to note that while oral hormonal contraceptives are highly effective at preventing pregnancy when used correctly, they do not protect against sexually transmitted infections (STIs). Therefore, it is still important to use barrier methods of protection, such as condoms, during sexual activity to reduce the risk of STIs.

As with any medication, oral hormonal contraceptives can have side effects and may not be suitable for everyone. It's important to discuss any medical conditions, allergies, or medications you are taking with your healthcare provider before starting to take oral hormonal contraceptives.

Estrogen Replacement Therapy (ERT) is a medical treatment in which estrogen hormones are administered to replace the estrogen that is naturally produced by the ovaries but declines, especially during menopause. This therapy is often used to help manage symptoms of menopause such as hot flashes, night sweats, and vaginal dryness. It can also help prevent bone loss in postmenopausal women. ERT typically involves the use of estrogen alone, but in some cases, a combination of estrogen and progestin may be prescribed for women with a uterus to reduce the risk of endometrial cancer. However, ERT is associated with certain risks, including an increased risk of breast cancer, blood clots, and stroke, so it's important for women to discuss the potential benefits and risks with their healthcare provider before starting this therapy.

The femoral vein is the large vein that runs through the thigh and carries oxygen-depleted blood from the lower limbs back to the heart. It is located in the femoral triangle, along with the femoral artery and nerve. The femoral vein begins at the knee as the popliteal vein, which then joins with the deep vein of the thigh to form the femoral vein. As it moves up the leg, it is joined by several other veins, including the great saphenous vein, before it becomes the external iliac vein at the inguinal ligament in the groin.

Early ambulation, also known as early mobilization or early rehabilitation, refers to the practice of encouraging patients to get out of bed and start moving around as soon as possible after a surgical procedure or medical event such as a stroke. The goal of early ambulation is to prevent complications associated with prolonged bed rest, including muscle weakness, joint stiffness, blood clots, pneumonia, and pressure ulcers. It can also help improve patients' overall recovery, strength, and functional ability.

The specific timeline for early ambulation will depend on the individual patient's medical condition and healthcare provider's recommendations. However, in general, it is recommended to start mobilizing patients as soon as they are medically stable and able to do so safely, often within the first 24-48 hours after surgery or an event. This may involve sitting up in bed, standing, taking a few steps with assistance, or walking a short distance with the help of a walker or other assistive device.

Healthcare providers such as physicians, nurses, and physical therapists work together to develop a safe and effective early ambulation plan for each patient, taking into account their individual needs, abilities, and limitations.

An intrauterine device (IUD) is a small, T-shaped birth control device that is inserted into the uterus to prevent pregnancy. A medicated IUD is a type of IUD that contains hormones, which are released slowly over time to provide additional benefits beyond just contraception.

There are two types of medicated IUDs available in the US market: levonorgestrel-releasing intrauterine system (LNG-IUS) and the copper intrauterine device (Cu-IUD). The LNG-IUS releases a progestin hormone called levonorgestrel, which thickens cervical mucus to prevent sperm from reaching the egg, thins the lining of the uterus to make it less likely for a fertilized egg to implant, and can also inhibit ovulation in some women. The Cu-IUD is non-hormonal and works by releasing copper ions that create a toxic environment for sperm, preventing them from reaching the egg.

Medicated IUDs are highly effective at preventing pregnancy, with typical use failure rates of less than 1% per year. They can remain in place for several years, depending on the brand, and can be removed at any time by a healthcare provider if a woman wants to become pregnant or experience side effects. Common side effects of medicated IUDs may include irregular menstrual bleeding, cramping, and spotting between periods, although these tend to improve over time.

Benzylamines are a class of organic compounds that consist of a benzene ring attached to an amine group. The amine group (-NH2) can be primary, secondary, or tertiary, depending on the number of hydrogen atoms bonded to the nitrogen atom. Benzylamines are used in the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds. They have a variety of biological activities and can act as central nervous system depressants, local anesthetics, and muscle relaxants. However, some benzylamines can also be toxic or carcinogenic, so they must be handled with care.

Postphlebitic syndrome, also known as postthrombotic syndrome or post-thrombotic limb, is a long-term complication that can occur after deep vein thrombosis (DVT). It's characterized by chronic venous insufficiency due to damage in the valves and walls of the affected veins. This results in impaired return of blood from the extremities back to the heart, leading to symptoms such as:

1. Swelling (edema) in the affected limb, usually the lower leg or calf.
2. Pain, aching, or cramping in the legs.
3. Heaviness or fatigue in the legs.
4. Skin changes like redness, warmth, or itchiness.
5. Development of venous ulcers or sores, particularly around the ankles.

The severity of postphlebitic syndrome can vary from mild to severe and may significantly impact a person's quality of life. Risk factors for developing this condition include having had a previous DVT, obesity, older age, lack of physical activity, and a family history of blood clotting disorders. Early diagnosis and appropriate management of deep vein thrombosis can help reduce the risk of developing postphlebitic syndrome.

An acute disease is a medical condition that has a rapid onset, develops quickly, and tends to be short in duration. Acute diseases can range from minor illnesses such as a common cold or flu, to more severe conditions such as pneumonia, meningitis, or a heart attack. These types of diseases often have clear symptoms that are easy to identify, and they may require immediate medical attention or treatment.

Acute diseases are typically caused by an external agent or factor, such as a bacterial or viral infection, a toxin, or an injury. They can also be the result of a sudden worsening of an existing chronic condition. In general, acute diseases are distinct from chronic diseases, which are long-term medical conditions that develop slowly over time and may require ongoing management and treatment.

Examples of acute diseases include:

* Acute bronchitis: a sudden inflammation of the airways in the lungs, often caused by a viral infection.
* Appendicitis: an inflammation of the appendix that can cause severe pain and requires surgical removal.
* Gastroenteritis: an inflammation of the stomach and intestines, often caused by a viral or bacterial infection.
* Migraine headaches: intense headaches that can last for hours or days, and are often accompanied by nausea, vomiting, and sensitivity to light and sound.
* Myocardial infarction (heart attack): a sudden blockage of blood flow to the heart muscle, often caused by a buildup of plaque in the coronary arteries.
* Pneumonia: an infection of the lungs that can cause coughing, chest pain, and difficulty breathing.
* Sinusitis: an inflammation of the sinuses, often caused by a viral or bacterial infection.

It's important to note that while some acute diseases may resolve on their own with rest and supportive care, others may require medical intervention or treatment to prevent complications and promote recovery. If you are experiencing symptoms of an acute disease, it is always best to seek medical attention to ensure proper diagnosis and treatment.

Azetidines are a class of organic compounds that contain a 4-membered saturated ring with two carbon atoms and two nitrogen atoms. The general structure of an azetidine is R-CH2-CH2-N-R', where R and R' can be hydrogen atoms or any other organic substituents.

Azetidines are relatively rare in nature, but they have attracted significant interest in the field of medicinal chemistry due to their unique structure and potential as building blocks for drug design. Some azetidine-containing compounds have been developed as drugs for various therapeutic indications, such as antibiotics, antivirals, and anti-inflammatory agents.

It's worth noting that the term 'azetidines' can also refer to the class of pharmaceutical compounds that contain an azetidine ring in their structure.

Blood coagulation disorders, also known as bleeding disorders or clotting disorders, refer to a group of medical conditions that affect the body's ability to form blood clots properly. Normally, when a blood vessel is injured, the body's coagulation system works to form a clot to stop the bleeding and promote healing.

In blood coagulation disorders, there can be either an increased tendency to bleed due to problems with the formation of clots (hemorrhagic disorder), or an increased tendency for clots to form inappropriately even without injury, leading to blockages in the blood vessels (thrombotic disorder).

Examples of hemorrhagic disorders include:

1. Hemophilia - a genetic disorder that affects the ability to form clots due to deficiencies in clotting factors VIII or IX.
2. Von Willebrand disease - another genetic disorder caused by a deficiency or abnormality of the von Willebrand factor, which helps platelets stick together to form a clot.
3. Liver diseases - can lead to decreased production of coagulation factors, increasing the risk of bleeding.
4. Disseminated intravascular coagulation (DIC) - a serious condition where clotting and bleeding occur simultaneously due to widespread activation of the coagulation system.

Examples of thrombotic disorders include:

1. Factor V Leiden mutation - a genetic disorder that increases the risk of inappropriate blood clot formation.
2. Antithrombin III deficiency - a genetic disorder that impairs the body's ability to break down clots, increasing the risk of thrombosis.
3. Protein C or S deficiencies - genetic disorders that lead to an increased risk of thrombosis due to impaired regulation of the coagulation system.
4. Antiphospholipid syndrome (APS) - an autoimmune disorder where the body produces antibodies against its own clotting factors, increasing the risk of thrombosis.

Treatment for blood coagulation disorders depends on the specific diagnosis and may include medications to manage bleeding or prevent clots, as well as lifestyle changes and monitoring to reduce the risk of complications.

Nadroparin is defined as a low molecular weight heparin (LMWH) drug, which is used as an anticoagulant. It is derived from unfractionated heparin and works by inhibiting the activity of coagulation factor Xa and to a lesser extent, thrombin. Nadroparin is commonly used for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for the management of unstable angina and non-Q wave myocardial infarction.

The drug is administered subcutaneously, and its anticoagulant effect is monitored by measuring the activated partial thromboplastin time (APTT) or anti-Xa activity. The half-life of nadroparin is approximately 4 hours, and it has a lower risk of heparin-induced thrombocytopenia (HIT) compared to unfractionated heparin.

It's important to note that the use of nadroparin or any other anticoagulant medication should be under the supervision of a healthcare professional, and patients should be closely monitored for bleeding risks and other potential adverse effects.

Antithrombin III is a protein that inhibits the formation of blood clots (thrombi) in the body. It does this by inactivating several enzymes involved in coagulation, including thrombin and factor Xa. Antithrombin III is produced naturally by the liver and is also available as a medication for the prevention and treatment of thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. It works by binding to and neutralizing excess clotting factors in the bloodstream, thereby reducing the risk of clot formation.

A registry in the context of medicine is a collection or database of standardized information about individuals who share a certain condition or attribute, such as a disease, treatment, exposure, or demographic group. These registries are used for various purposes, including:

* Monitoring and tracking the natural history of diseases and conditions
* Evaluating the safety and effectiveness of medical treatments and interventions
* Conducting research and generating hypotheses for further study
* Providing information to patients, clinicians, and researchers
* Informing public health policy and decision-making

Registries can be established for a wide range of purposes, including disease-specific registries (such as cancer or diabetes registries), procedure-specific registries (such as joint replacement or cardiac surgery registries), and population-based registries (such as birth defects or cancer registries). Data collected in registries may include demographic information, clinical data, laboratory results, treatment details, and outcomes.

Registries can be maintained by a variety of organizations, including hospitals, clinics, academic medical centers, professional societies, government agencies, and industry. Participation in registries is often voluntary, although some registries may require informed consent from participants. Data collected in registries are typically de-identified to protect the privacy of individuals.

Protein S is a vitamin K-dependent protein found in the blood that functions as a natural anticoagulant. It plays a crucial role in regulating the body's clotting system by inhibiting the activation of coagulation factors, thereby preventing excessive blood clotting. Protein S also acts as a cofactor for activated protein C, which is another important anticoagulant protein.

Protein S exists in two forms: free and bound to a protein called C4b-binding protein (C4BP). Only the free form of Protein S has biological activity in inhibiting coagulation. Inherited or acquired deficiencies in Protein S can lead to an increased risk of thrombosis, or abnormal blood clot formation, which can cause various medical conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Regular monitoring of Protein S levels is essential for patients with a history of thrombotic events or those who have a family history of thrombophilia.

Chemoprevention is a medical term that refers to the use of chemical agents, usually in the form of drugs or dietary supplements, to prevent or delay the development of cancer. These agents are typically designed to interfere with the molecular processes involved in cancer initiation, promotion, or progression.

There are several different approaches to chemoprevention, depending on the specific type of cancer and the individual patient's risk factors. Some chemopreventive agents work by blocking the action of hormones that can promote cancer growth, while others may inhibit the activity of enzymes involved in DNA damage or repair.

Chemoprevention is often used in individuals who are at high risk of developing cancer due to inherited genetic mutations, a history of precancerous lesions, or other factors. However, it is important to note that chemopreventive agents can have side effects and may not be appropriate for everyone. Therefore, they should only be used under the close supervision of a healthcare provider.

I'm sorry for any confusion, but "United States" is a geopolitical entity, specifically the name of the country consisting of 50 states, and it is not a medical term or concept. Therefore, I can't provide a medical definition for it. If you have any questions related to health, medicine, or biology, I would be happy to try to help answer those!

I'm sorry for any confusion, but "Massachusetts" is not a medical term. It is the name of a state located in the northeastern region of the United States. If you have any questions about medical terms or concepts, I would be happy to help clarify those for you.

An "aircraft" is not a medical term, but rather a general term used to describe any vehicle or machine designed to be powered and operated in the air. This includes fixed-wing aircraft such as airplanes and gliders, as well as rotary-wing aircraft such as helicopters and autogyros.

However, there are some medical conditions that can affect a person's ability to safely operate an aircraft, such as certain cardiovascular or neurological disorders. In these cases, the individual may be required to undergo medical evaluation and obtain clearance from aviation medical examiners before they are allowed to fly.

Additionally, there are some medical devices and equipment that are used in aircraft, such as oxygen systems and medical evacuation equipment. These may be used to provide medical care to passengers or crew members during flight.

A stroke, also known as cerebrovascular accident (CVA), is a serious medical condition that occurs when the blood supply to part of the brain is interrupted or reduced, leading to deprivation of oxygen and nutrients to brain cells. This can result in the death of brain tissue and cause permanent damage or temporary impairment to cognitive functions, speech, memory, movement, and other body functions controlled by the affected area of the brain.

Strokes can be caused by either a blockage in an artery that supplies blood to the brain (ischemic stroke) or the rupture of a blood vessel in the brain (hemorrhagic stroke). A transient ischemic attack (TIA), also known as a "mini-stroke," is a temporary disruption of blood flow to the brain that lasts only a few minutes and does not cause permanent damage.

Symptoms of a stroke may include sudden weakness or numbness in the face, arm, or leg; difficulty speaking or understanding speech; vision problems; loss of balance or coordination; severe headache with no known cause; and confusion or disorientation. Immediate medical attention is crucial for stroke patients to receive appropriate treatment and prevent long-term complications.

Tertiary prevention in a medical context refers to measures aimed at managing or reducing the negative impact of an existing disease or disorder, with the goal of improving the patient's quality of life and preventing further complications or disability. It involves rehabilitation, long-term supportive care, and management of symptoms or complications associated with chronic conditions.

Tertiary prevention strategies may include:

1. Rehabilitation programs to help patients regain lost function, mobility, or skills.
2. Symptom management through medications, therapies, or surgical interventions.
3. Education and counseling on lifestyle modifications to minimize the risk of complications.
4. Regular monitoring and follow-up care to detect and address any new issues early.
5. Supportive care to help patients cope with chronic conditions and maintain their independence.

Examples of tertiary prevention include physical therapy for someone recovering from a stroke, pain management strategies for individuals with chronic pain, or regular monitoring and treatment of complications in people with diabetes.

Comorbidity is the presence of one or more additional health conditions or diseases alongside a primary illness or condition. These co-occurring health issues can have an impact on the treatment plan, prognosis, and overall healthcare management of an individual. Comorbidities often interact with each other and the primary condition, leading to more complex clinical situations and increased healthcare needs. It is essential for healthcare professionals to consider and address comorbidities to provide comprehensive care and improve patient outcomes.

Conduction anesthesia is a type of local anesthesia in which an anesthetic agent is administered near a peripheral nerve to block the transmission of painful stimuli. It is called "conduction" anesthesia because it works by blocking the conduction of nerve impulses along the nerve fibers.

There are several types of conduction anesthesia, including:

1. Infiltration anesthesia: In this technique, the anesthetic agent is injected directly into the tissue where the surgical procedure will be performed. This type of anesthesia can be used for minor surgeries such as wound closure or repair of simple lacerations.
2. Nerve block anesthesia: In this technique, the anesthetic agent is injected near a specific nerve or bundle of nerves to block sensation in a larger area of the body. For example, a brachial plexus block can be used to numb the arm and hand for procedures such as shoulder surgery or fracture reduction.
3. Field block anesthesia: In this technique, the anesthetic agent is injected around the periphery of the surgical site to create a "field" of anesthesia that blocks sensation in the area. This type of anesthesia is often used for procedures such as hernia repair or circumcision.

Conduction anesthesia has several advantages over general anesthesia, including reduced risk of complications, faster recovery time, and lower cost. However, it may not be appropriate for all types of surgical procedures or patients, and its effectiveness can vary depending on the skill of the practitioner and the individual patient's response to the anesthetic agent.

Proportional hazards models are a type of statistical analysis used in medical research to investigate the relationship between covariates (predictor variables) and survival times. The most common application of proportional hazards models is in the Cox regression model, which is named after its developer, Sir David Cox.

In a proportional hazards model, the hazard rate or risk of an event occurring at a given time is assumed to be proportional to the hazard rate of a reference group, after adjusting for the covariates. This means that the ratio of the hazard rates between any two individuals remains constant over time, regardless of their survival times.

Mathematically, the hazard function h(t) at time t for an individual with a set of covariates X can be expressed as:

h(t|X) = h0(t) \* exp(β1X1 + β2X2 + ... + βpXp)

where h0(t) is the baseline hazard function, X1, X2, ..., Xp are the covariates, and β1, β2, ..., βp are the regression coefficients that represent the effect of each covariate on the hazard rate.

The assumption of proportionality is crucial in the interpretation of the results from a Cox regression model. If the assumption is violated, then the estimated regression coefficients may be biased and misleading. Therefore, it is important to test for the proportional hazards assumption before interpreting the results of a Cox regression analysis.

The odds ratio (OR) is a statistical measure used in epidemiology and research to estimate the association between an exposure and an outcome. It represents the odds that an event will occur in one group versus the odds that it will occur in another group, assuming that all other factors are held constant.

In medical research, the odds ratio is often used to quantify the strength of the relationship between a risk factor (exposure) and a disease outcome. An OR of 1 indicates no association between the exposure and the outcome, while an OR greater than 1 suggests that there is a positive association between the two. Conversely, an OR less than 1 implies a negative association.

It's important to note that the odds ratio is not the same as the relative risk (RR), which compares the incidence rates of an outcome in two groups. While the OR can approximate the RR when the outcome is rare, they are not interchangeable and can lead to different conclusions about the association between an exposure and an outcome.

Fibrin clot lysis time, also known as fibrinolytic time, is the measurement of the amount of time it takes for a blood clot to dissolve or lyse. This is typically measured in a laboratory setting using specialized tests such as the thromboelastography (TEG) or rotational thromboelastometry (ROTEM) assays. These tests measure the viscoelastic properties of a clot and can provide information about the rate of fibrinolysis, which is the natural process by which the body breaks down and removes blood clots.

Increased fibrin clot lysis time may indicate an impaired fibrinolytic system, which can lead to an increased risk of thrombosis or blood clot formation. Decreased fibrin clot lysis time may indicate an overactive fibrinolytic system, which can lead to an increased risk of bleeding.

It's important to note that the fibrin clot lysis time is just one factor among many that are considered when evaluating a patient's coagulation status and risk of thrombosis or bleeding. Other factors, such as platelet function, coagulation factor levels, and the presence of inhibitors or anticoagulants, must also be taken into account.

An embolectomy is a surgical procedure to remove an embolus, which is a blockage in a blood vessel caused by a clot or air bubble that has traveled from another part of the body. During an embolectomy, the surgeon makes an incision in the affected blood vessel and removes the embolus using specialized surgical instruments. This procedure is often performed as an emergency treatment to restore blood flow and prevent tissue damage in the affected area of the body.

Central venous catheterization is a medical procedure in which a flexible tube called a catheter is inserted into a large vein in the body, usually in the neck (internal jugular vein), chest (subclavian vein), or groin (femoral vein). The catheter is threaded through the vein until it reaches a central location, such as the superior vena cava or the right atrium of the heart.

Central venous catheterization may be performed for several reasons, including:

1. To administer medications, fluids, or nutritional support directly into the bloodstream.
2. To monitor central venous pressure (CVP), which can help assess a patient's volume status and cardiac function.
3. To draw blood samples for laboratory tests.
4. To deliver chemotherapy drugs or other medications that may be harmful to peripheral veins.
5. To provide access for hemodialysis or other long-term therapies.

The procedure requires careful attention to sterile technique to minimize the risk of infection, and it is usually performed under local anesthesia with sedation or general anesthesia. Complications of central venous catheterization may include bleeding, infection, pneumothorax (collapsed lung), arterial puncture, and catheter-related bloodstream infections (CRBSI).

Progestins are a class of steroid hormones that are similar to progesterone, a natural hormone produced by the ovaries during the menstrual cycle and pregnancy. They are often used in hormonal contraceptives, such as birth control pills, shots, and implants, to prevent ovulation and thicken the cervical mucus, making it more difficult for sperm to reach the egg. Progestins are also used in menopausal hormone therapy to alleviate symptoms of menopause, such as hot flashes and vaginal dryness. Additionally, progestins may be used to treat endometriosis, uterine fibroids, and breast cancer. Different types of progestins have varying properties and may be more suitable for certain indications or have different side effect profiles.

Traumatic Intracranial Hemorrhage (TIH) is a type of bleeding that occurs within the skull or inside the brain parenchyma as a result of traumatic injury. It can be further classified based on the location and type of bleeding, which includes:

1. Epidural hematoma (EDH): Bleeding between the dura mater and the inner table of the skull, usually caused by arterial bleeding from the middle meningeal artery after a temporal bone fracture.
2. Subdural hematoma (SDH): Bleeding in the potential space between the dura mater and the arachnoid membrane, often due to venous sinus or bridging vein injury. SDHs can be acute, subacute, or chronic based on their age and clinical presentation.
3. Subarachnoid hemorrhage (SAH): Bleeding into the subarachnoid space, which is filled with cerebrospinal fluid (CSF). SAH is commonly caused by trauma but can also be secondary to aneurysmal rupture or arteriovenous malformations.
4. Intraparenchymal hemorrhage (IPH): Bleeding directly into the brain parenchyma, which can result from contusions, lacerations, or shearing forces during traumatic events.
5. Intraventricular hemorrhage (IVH): Bleeding into the cerebral ventricles, often as a complication of IPH, SAH, or EDH. IVH can lead to obstructive hydrocephalus and increased intracranial pressure (ICP).

TIHs are medical emergencies requiring prompt diagnosis and management to prevent secondary brain injury and reduce morbidity and mortality. Imaging modalities such as computed tomography (CT) or magnetic resonance imaging (MRI) are used for the detection and characterization of TIHs, while neurosurgical intervention may be necessary in specific cases.

Operative surgical procedures refer to medical interventions that involve manual manipulation of tissues, structures, or organs in the body, typically performed in an operating room setting under sterile conditions. These procedures are carried out with the use of specialized instruments, such as scalpels, forceps, and scissors, and may require regional or general anesthesia to ensure patient comfort and safety.

Operative surgical procedures can range from relatively minor interventions, such as a biopsy or the removal of a small lesion, to more complex and extensive surgeries, such as open heart surgery or total joint replacement. The specific goals of operative surgical procedures may include the diagnosis and treatment of medical conditions, the repair or reconstruction of damaged tissues or organs, or the prevention of further disease progression.

Regardless of the type or complexity of the procedure, all operative surgical procedures require careful planning, execution, and postoperative management to ensure the best possible outcomes for patients.

Primary prevention in a medical context refers to actions taken to prevent the development of a disease or injury before it occurs. This is typically achieved through measures such as public health education, lifestyle modifications, and vaccinations. The goal of primary prevention is to reduce the risk of a disease or injury by addressing its underlying causes. Examples of primary prevention strategies include smoking cessation programs to prevent lung cancer, immunizations to prevent infectious diseases, and safety regulations to prevent accidents and injuries.

The Predictive Value of Tests, specifically the Positive Predictive Value (PPV) and Negative Predictive Value (NPV), are measures used in diagnostic tests to determine the probability that a positive or negative test result is correct.

Positive Predictive Value (PPV) is the proportion of patients with a positive test result who actually have the disease. It is calculated as the number of true positives divided by the total number of positive results (true positives + false positives). A higher PPV indicates that a positive test result is more likely to be a true positive, and therefore the disease is more likely to be present.

Negative Predictive Value (NPV) is the proportion of patients with a negative test result who do not have the disease. It is calculated as the number of true negatives divided by the total number of negative results (true negatives + false negatives). A higher NPV indicates that a negative test result is more likely to be a true negative, and therefore the disease is less likely to be present.

The predictive value of tests depends on the prevalence of the disease in the population being tested, as well as the sensitivity and specificity of the test. A test with high sensitivity and specificity will generally have higher predictive values than a test with low sensitivity and specificity. However, even a highly sensitive and specific test can have low predictive values if the prevalence of the disease is low in the population being tested.

Prevalence, in medical terms, refers to the total number of people in a given population who have a particular disease or condition at a specific point in time, or over a specified period. It is typically expressed as a percentage or a ratio of the number of cases to the size of the population. Prevalence differs from incidence, which measures the number of new cases that develop during a certain period.

Logistic models, specifically logistic regression models, are a type of statistical analysis used in medical and epidemiological research to identify the relationship between the risk of a certain health outcome or disease (dependent variable) and one or more independent variables, such as demographic factors, exposure variables, or other clinical measurements.

In contrast to linear regression models, logistic regression models are used when the dependent variable is binary or dichotomous in nature, meaning it can only take on two values, such as "disease present" or "disease absent." The model uses a logistic function to estimate the probability of the outcome based on the independent variables.

Logistic regression models are useful for identifying risk factors and estimating the strength of associations between exposures and health outcomes, adjusting for potential confounders, and predicting the probability of an outcome given certain values of the independent variables. They can also be used to develop clinical prediction rules or scores that can aid in decision-making and patient care.

Thrombolytic therapy, also known as thrombolysis, is a medical treatment that uses medications called thrombolytics or fibrinolytics to dissolve or break down blood clots (thrombi) in blood vessels. These clots can obstruct the flow of blood to vital organs such as the heart, lungs, or brain, leading to serious conditions like myocardial infarction (heart attack), pulmonary embolism, or ischemic stroke.

The goal of thrombolytic therapy is to restore blood flow as quickly and efficiently as possible to prevent further damage to the affected organ and potentially save lives. Commonly used thrombolytic drugs include alteplase (tPA), reteplase, and tenecteplase. It's essential to administer these medications as soon as possible after the onset of symptoms for optimal treatment outcomes. However, there are risks associated with thrombolytic therapy, such as an increased chance of bleeding complications, which must be carefully weighed against its benefits in each individual case.

Atrial fibrillation (A-tre-al fi-bru-la'shun) is a type of abnormal heart rhythm characterized by rapid and irregular beating of the atria, the upper chambers of the heart. In this condition, the electrical signals that coordinate heartbeats don't function properly, causing the atria to quiver instead of contracting effectively. As a result, blood may not be pumped efficiently into the ventricles, which can lead to blood clots, stroke, and other complications. Atrial fibrillation is a common type of arrhythmia and can cause symptoms such as palpitations, shortness of breath, fatigue, and dizziness. It can be caused by various factors, including heart disease, high blood pressure, age, and genetics. Treatment options include medications, electrical cardioversion, and surgical procedures to restore normal heart rhythm.

Thrombin is a serine protease enzyme that plays a crucial role in the coagulation cascade, which is a complex series of biochemical reactions that leads to the formation of a blood clot (thrombus) to prevent excessive bleeding during an injury. Thrombin is formed from its precursor protein, prothrombin, through a process called activation, which involves cleavage by another enzyme called factor Xa.

Once activated, thrombin converts fibrinogen, a soluble plasma protein, into fibrin, an insoluble protein that forms the structural framework of a blood clot. Thrombin also activates other components of the coagulation cascade, such as factor XIII, which crosslinks and stabilizes the fibrin network, and platelets, which contribute to the formation and growth of the clot.

Thrombin has several regulatory mechanisms that control its activity, including feedback inhibition by antithrombin III, a plasma protein that inactivates thrombin and other serine proteases, and tissue factor pathway inhibitor (TFPI), which inhibits the activation of factor Xa, thereby preventing further thrombin formation.

Overall, thrombin is an essential enzyme in hemostasis, the process that maintains the balance between bleeding and clotting in the body. However, excessive or uncontrolled thrombin activity can lead to pathological conditions such as thrombosis, atherosclerosis, and disseminated intravascular coagulation (DIC).

A hip fracture is a medical condition referring to a break in the upper part of the femur (thigh) bone, which forms the hip joint. The majority of hip fractures occur due to falls or direct trauma to the area. They are more common in older adults, particularly those with osteoporosis, a condition that weakens bones and makes them more prone to breaking. Hip fractures can significantly impact mobility and quality of life, often requiring surgical intervention and rehabilitation.

The Kaplan-Meier estimate is a statistical method used to calculate the survival probability over time in a population. It is commonly used in medical research to analyze time-to-event data, such as the time until a patient experiences a specific event like disease progression or death. The Kaplan-Meier estimate takes into account censored data, which occurs when some individuals are lost to follow-up before experiencing the event of interest.

The method involves constructing a survival curve that shows the proportion of subjects still surviving at different time points. At each time point, the survival probability is calculated as the product of the conditional probabilities of surviving from one time point to the next. The Kaplan-Meier estimate provides an unbiased and consistent estimator of the survival function, even when censoring is present.

In summary, the Kaplan-Meier estimate is a crucial tool in medical research for analyzing time-to-event data and estimating survival probabilities over time while accounting for censored observations.

Elective surgical procedures are operations that are scheduled in advance because they do not involve a medical emergency. These surgeries are chosen or "elective" based on the patient's and doctor's decision to improve the patient's quality of life or to treat a non-life-threatening condition. Examples include but are not limited to:

1. Aesthetic or cosmetic surgery such as breast augmentation, rhinoplasty, etc.
2. Orthopedic surgeries like knee or hip replacements
3. Cataract surgery
4. Some types of cancer surgeries where the tumor is not spreading or causing severe symptoms
5. Gastric bypass for weight loss

It's important to note that while these procedures are planned, they still require thorough preoperative evaluation and preparation, and carry risks and benefits that need to be carefully considered by both the patient and the healthcare provider.

Impedance plethysmography is a non-invasive method used to measure changes in blood volume or flow in a particular area of the body. It works by passing a small electrical current through the tissue and measuring the opposition (impedance) to that current, which varies with the amount of blood present in the area.

In impedance cardiography, this technique is used to estimate cardiac output, stroke volume, and other hemodynamic parameters. The changes in impedance are measured across the chest wall, which correlate with the ventricular ejection of blood during each heartbeat. This allows for the calculation of various cardiovascular variables, such as the amount of blood pumped by the heart per minute (cardiac output) and the resistance to blood flow in the systemic circulation (systemic vascular resistance).

Impedance plethysmography is a safe and reliable method for assessing cardiovascular function, and it has been widely used in clinical settings to evaluate patients with various cardiovascular disorders, including heart failure, hypertension, and peripheral arterial disease.

Cell-derived microparticles (CDMs), also known as microvesicles or microparticles, are small membrane-bound particles that are released from the cell surface upon activation or apoptosis of various cell types, including platelets, leukocytes, endothelial cells, and red blood cells. CDMs range in size from 0.1 to 1.0 micrometers in diameter and contain a variety of bioactive molecules, such as lipids, proteins, and nucleic acids, which can be transferred to neighboring or distant cells, thereby modulating their function.

CDMs have been implicated in various physiological and pathological processes, including coagulation, inflammation, immune response, angiogenesis, and cancer progression. They have also emerged as potential biomarkers for various diseases, such as cardiovascular disease, sepsis, and cancer, due to their distinct molecular signature and abundance in body fluids, such as blood, urine, and cerebrospinal fluid.

The mechanisms of CDM formation and release are complex and involve several cellular processes, including cytoskeletal rearrangement, membrane budding, and vesicle shedding. The molecular composition of CDMs reflects their cellular origin and activation state, and can be analyzed by various techniques, such as flow cytometry, proteomics, and transcriptomics, to gain insights into their biological functions and clinical relevance.

I'm not sure I understand your question. "Denmark" is a country located in Northern Europe, and it is not a medical term or concept. It is the southernmost of the Nordic countries, and it consists of the Jutland peninsula and several islands in the Baltic Sea. The capital city of Denmark is Copenhagen.

If you are looking for information about a medical condition that may be associated with Denmark, could you please provide more context or clarify your question? I would be happy to help you with more specific information if I can.

Intention-to-treat (ITT) analysis is a principle used in the design and interpretation of clinical trials, where all participants who are randomly assigned to a treatment group, regardless of whether they receive or complete the intended intervention, are included in the final analysis. The primary aim of ITT analysis is to mirror real-world scenarios as closely as possible by preserving the original randomization scheme and accounting for potential confounding factors, such as dropouts, protocol deviations, or crossovers between treatment groups.

In an ITT analysis, participants are analyzed in their originally assigned groups, even if they do not receive the intended intervention or switch to another group during the study. This approach helps maintain the balance of prognostic factors across treatment groups and reduces bias that may arise from selective exclusion of non-compliant or non-adherent individuals.

The ITT principle is particularly important in superiority trials, where the primary goal is to demonstrate a significant difference between two interventions. By including all participants in the analysis, researchers can minimize potential biases and maintain statistical power, ensuring that the results are more generalizable to the broader target population. However, it is essential to recognize that ITT analyses may underestimate treatment effects compared to per-protocol or as-treated analyses, which only include participants who adhere to their assigned intervention.

In summary, an intention-to-treat analysis is a medical research principle in clinical trials where all randomly assigned participants are analyzed in their original groups, regardless of whether they receive or complete the intended intervention. This approach helps maintain statistical power and reduce bias, providing results that are more generalizable to real-world scenarios.

A thrombectomy is a medical procedure that involves the removal of a blood clot (thrombus) from a blood vessel. This is typically performed to restore blood flow in cases where the clot is causing significant blockage, which can lead to serious complications such as tissue damage or organ dysfunction.

During a thrombectomy, a surgeon makes an incision and accesses the affected blood vessel, often with the help of imaging guidance. Specialized tools are then used to extract the clot, after which the blood vessel is usually repaired. Thrombectomies can be performed on various blood vessels throughout the body, including those in the brain, heart, lungs, and limbs.

This procedure may be recommended for patients with deep vein thrombosis (DVT), pulmonary embolism (PE), or certain types of stroke, depending on the specific circumstances and the patient's overall health. It is generally considered when anticoagulation therapy or clot-dissolving medications are not sufficient or appropriate to treat the blood clot.

The Estrogen in Venous Thromboembolism Trial (EVTET) was a randomized controlled trial (RCT) of menopausal hormone therapy in ... Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM (August 2018). "Risk of venous thromboembolism events in ... Lobo RA (May 2011). "Risk of venous thromboembolism by route of administration of estrogen". Menopause. 18 (5): 469-70. doi: ... Scarabin PY (August 2018). "Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal ...
Dalen, James E. (2003). Venous Thromboembolism. New York: Marcel Decker, Inc. ISBN 978-0-8247-5645-1. Reese, DM (1998). " ... He noted that blood clots in the pulmonary artery originate first from venous thrombi, stating in 1859: [T]he detachment of ... During his six-year period there, he concentrated on his scientific work, including detailed studies of venous thrombosis and ... Virchow is also known for elucidating the mechanism of pulmonary thromboembolism (a condition of blood clotting in the blood ...
2007). "Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of ... Khan, Faizan; Tritschler, Tobias; Kahn, Susan R; Rodger, Marc A (2021). "Venous thromboembolism". The Lancet. 398 (10294): 64- ... such as venous thromboembolism. While a negative result practically rules out thrombosis, a positive result can indicate ... for patients aged over 50 years for the suspicion of venous thromboembolism (VTE), as it decreases the false positive rate ...
"Venous thromboembolism". Royal College of Nursing. Retrieved 4 September 2012. "Mission Statement". Lifeblood, the Thrombosis ... campaign aims to ensure that every adult patient admitted to hospital across the UK receives a venous thromboembolism risk ... They also strive to improve the clinical diagnosis of venous thromboembolism in the community ('Spot the Clots'). Thrombosis UK ... they campaign for governments in the UK to prioritise venous thromboembolism (VTE) prevention in the National Health Service (' ...
"Venous thromboembolism (VTE) , McMaster Pathophysiology Review". www.pathophys.org. 26 September 2012. Retrieved 2018-11-03. ... all of which contribute to increased risk for venous thromboembolism and other cardiovascular diseases. Virchow's triad ... A venous embolus (mostly from deep vein thrombosis in the lower limbs) will travel through the systemic circulation, reach the ... Venous or red thrombi (characterized by predominance of red blood cells). In the microcirculation consisting of the very small ...
"American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context ... "American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism ... recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism ... "American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous ...
Heit JA, Spencer FA, White RH (2016). "The epidemiology of venous thromboembolism". J. Thromb. Thrombolysis. 41 (1): 3-14. doi: ... 665-. ISBN 978-0-323-29738-7. Ralli E, Zezza L, Caserta D (2014). "Pregnancy and venous thromboembolism". Curr. Opin. Obstet. ... Stanczyk FZ, Grimes DA (September 2008). "Sex hormone-binding globulin: not a surrogate marker for venous thromboembolism in ... Bińkowska M (October 2014). "Menopausal hormone therapy and venous thromboembolism". Prz Menopauzalny. 13 (5): 267-72. doi: ...
Venous thromboembolism (VTE) consists of deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT is a blood clot in a deep ... Beyer-Westendorf J, Werth S, Halbritter K, Weiss N (April 2010). "Cancer in males and risk of venous thromboembolism". Thromb. ... Seaman HE, Langley SE, Farmer RD, de Vries CS (June 2007). "Venous thromboembolism and cyproterone acetate in men with prostate ... Beyer-Westendorf J, Bauersachs R, Hach-Wunderle V, Zotz RB, Rott H (October 2018). "Sex hormones and venous thromboembolism - ...
Thrombophilia and Venous Thromboembolism and The prevention of Venous Thromboembolism. Nicolaides A. (1975). Thromboembolism - ... 1994). Prevention of Venous Thromboembolism, Med-Orion Publishing. ISBN 978-9963-592-52-4 Belcaro G. et al. (1995). Venous ... Nicolaides has undertaken research on venous thromboembolism, noninvasive vascular investigations with particular emphasis on ... ISBN 978-1-86094-213-6 Nicolaides A. (2002). Prevention of Venous Thromboembolism, International Consensus Statement ( ...
"Venous Thromboembolism (Blood Clots) Facts". Division of Blood Disorders National Center on Birth Defects and Developmental ... "Venous Thromboembolism (VTE)" (PDF). National Center on Birth Defects and Developmental Disabilities. Archived from the ... "Patients with Venous Thromboembolism ) Registry". RIETE. Retrieved 2016-12-20. Moliterno D (2013). Therapeutic advances in ... Kakkar VV, Cohen AT, Mohamed MS (1996). "Patients at risk of venous thromboembolism-clinical results with reviparin". ...
"Management of Venous Thromboembolism". ACS Surgery. American College of Surgeons. Archived from the original on January 27, ... PCD is fully reversible if the causal venous thrombus is promptly removed. In the 40-60% of people who go on to develop venous ... impending venous gangrene (blistering, weak sensory-motor function and weak distal pulses) Grade III = venous gangrene PCD is ... When a thrombus occludes an extremity vein, pressure backs up in the venous system leading plasma fluid to leak out into the ...
Venography in iliofemoral venous thromboembolism. Surg Gynecol Obstet 1969;129:57. Wolf, GL; Arenson, RL; Cross, AP. A ... In that sense, venous blood has a greater ability to reflect light. When an arterial-venous fistulae is transluminated, there ... Venous disorders: a manual of diagnosis and treatment. Cidade: Saundres; 1995:41. Cranley, JJ. Diagnostic tests for venous ... Chronic venous thrombosis and venous insufficiency. In: Peripheral vascular sonography: a practical guide. Baltimore: Williams ...
Many lawsuits have been filed against Bayer, the manufacturer of drospirenone, due to the higher risk of venous thromboembolism ... Heit JA, Spencer FA, White RH (2016). "The epidemiology of venous thromboembolism". J. Thromb. Thrombolysis. 41 (1): 3-14. doi: ... Sehovic N, Smith KP (May 2010). "Risk of venous thromboembolism with drospirenone in combined oral contraceptive products". Ann ... Toni I, Neubert A, Botzenhardt S, Gratzki N, Rascher W (September 2013). "Venous thromboembolism in adolescents associated with ...
Having a DVT or PE and a strong family history of venous thromboembolism. The use of hormones, such as oral contraceptive pills ... Despite the increased risk of venous thromboembolisms, people with one copy of this gene have not been found to have shorter ... Implications for venous thromboembolism screening". JAMA. 277 (16): 1305-7. doi:10.1001/jama.277.16.1305. PMID 9109469. Gregg ... November 2019). "Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with ...
In comparison, venous thromboembolism occurs in 100-200 per 100.000 pregnant women every year. One study showed more than a 600 ... All COCP users have a small increase in the risk of venous thromboembolism compared with non-users; this risk is greatest ... Combined oral contraceptives increase the risk of venous thromboembolism (including deep vein thrombosis (DVT) and pulmonary ... ISBN 978-0-7020-3471-8. ESHRE Capri Workshop Group (2013). "Venous thromboembolism in women: a specific reproductive health ...
"Venous thromboembolism - reducing the risk". Guidance.nice.org.uk. 2013-11-07. Retrieved 2014-01-16. "VTE prevention". Guidance ... She is a member of "The Independent Expert Panel on Venous Thromboembolism" 2005/6, and co-author on the "International ... She has a specialist clinical and research interest in venous thromboembolism, thromboprophylaxis, antiphospholipid syndrome, ... "Acute management of venous thromboembolism" published in 2012. On behalf of Thrombosis UK, she was also a member of the ...
Reitsma PH, Versteeg HH, Middeldorp S (2012). "Mechanistic view of risk factors for venous thromboembolism". Arterioscler ... Zakai, NA; McClure, LA (October 2011). "Racial differences in venous thromboembolism". Journal of Thrombosis and Haemostasis ( ... prothrombin G20210A is one of the most common genetic risk factors for venous thromboembolism (VTE). Increased production of ... mutations in adults with a history of idiopathic venous thromboembolism and their adult family members". Genetics in Medicine. ...
Renoux C, Dell'Aniello S, Suissa S (May 2010). "Hormone replacement therapy and the risk of venous thromboembolism: a ... 157-. ISBN 978-92-832-1291-1. Heit JA, Spencer FA, White RH (January 2016). "The epidemiology of venous thromboembolism". ... in women and does not increase the risk of venous thromboembolism (VTE) (RRTooltip Rate ratio = 0.92), which would not be ...
ISBN 978-3-319-65226-9. Ro A, Kageyama N, Mukai T (June 2017). "Pathophysiology of Venous Thromboembolism with Respect to the ... Heit JA, Spencer FA, White RH (January 2016). "The epidemiology of venous thromboembolism". Journal of Thrombosis and ... Most PEs are sequelae of Deep Vein Thrombosis (DVT), resulting from the breakage and propagation of a venous thrombus formed ... Jung J, Bonde P (2018). "Surgical Management of Pulmonary Embolism". In Chaar CI (ed.). Current Management of Venous Diseases. ...
November 2021). "Milvexian for the Prevention of Venous Thromboembolism". The New England Journal of Medicine. 385 (23): 2161- ... "Abelacimab for Prevention of Venous Thromboembolism". New England Journal of Medicine. 385 (7): 609-617. doi:10.1056/ ...
An estimated 64 percent of patients with venous thromboembolism may have APC resistance.[needs update] The disorder can be ... Sheppard DR (2000). "Activated protein C resistance: the most common risk factor for venous thromboembolism". J Am Board Fam ... Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J (2021). "Combined Oral Contraceptives and Venous Thromboembolism: Review ... Douxfils J, Morimont L, Bouvy C (November 2020). "Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May ...
When venous thromboembolism occurs when a patient is experiencing transient major risk factors such as prolonged immobility, ... Comp PC, Esmon CT (December 1984). "Recurrent venous thromboembolism in patients with a partial deficiency of protein S". N. ... Prandoni P, Falanga A, Piccioli A (June 2005). "Cancer and venous thromboembolism". Lancet Oncol. 6 (6): 401-10. doi:10.1016/ ... Dalen JE (June 2008). "Should patients with venous thromboembolism be screened for thrombophilia?". Am. J. Med. 121 (6): 458-63 ...
Bińkowska M (October 2014). "Menopausal hormone therapy and venous thromboembolism". Prz Menopauzalny. 13 (5): 267-72. doi: ... Scarabin PY (December 2014). "Hormones and venous thromboembolism among postmenopausal women". Climacteric. 17 (Suppl 2): 34-7 ... incidence of venous thromboembolism. In a small study comparing high-dosage 320 mg/month intramuscular polyestradiol phosphate ... "Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills ...
Massimo, F.; Mannucci, P.M (2016). "Direct oral anticoagulants and venous thromboembolism". European Respiratory Review. 25 ( ... was granted marketing authorization for the prevention of venous thromboembolism in Europe and Canada in September 2008. ...
This type of embolism is known as a thromboembolism. Complications can arise when a venous thromboembolism (commonly called a ... Clinical guideline 46: Venous thromboembolism (surgical). London, April 2007. Geerts WH, Pineo GF, Heit JA, et al. (September ... Clinical guideline 92: Venous thromboembolism: reducing the risk for patients in hospital. London, January 2010. Hunt BJ (March ... Cerebral venous sinus thrombosis (CVST) is a rare form of stroke which results from the blockage of the dural venous sinuses by ...
D-dimer for venous thromboembolism diagnosis: Twenty years later. Oral rivaroxaban for the treatment of symptomatic pulmonary ... Righini, M.; Perrier, A.; De Moerloose, P.; Bounameaux, H. (July 2008). "D-Dimer for venous thromboembolism diagnosis: 20 years ... His research interests cover all aspects related to the prevention, diagnosis, and treatment of venous thromboembolism. His ... Righini, M.; Perrier, A.; De Moerloose, P.; Bounameaux, H. (2008-07-02). "D-Dimer for venous thromboembolism diagnosis: 20 ...
The EINSTEIN Investigators (22 December 2010). "Oral Rivaroxaban for Symptomatic Venous Thromboembolism". New England Journal ... "Oral Apixaban for the Treatment of Acute Venous Thromboembolism". New England Journal of Medicine. 369 (9): 799-808. doi: ... "Apixaban for Extended Treatment of Venous Thromboembolism". New England Journal of Medicine. 368 (8): 699-708. doi:10.1056/ ...
Patients with cancer are at higher risk of venous thromboembolism and LMWHs are used to reduce this risk. The CLOT study, ... They are used in the prevention of blood clots and treatment of venous thromboembolism (deep vein thrombosis and pulmonary ... July 2003). "Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients ... Once or twice daily subcutaneous injection for treatment of venous thromboembolism and in unstable angina instead of ...
... and overall mortality A risk factor for venous thromboembolism Microalbuminuria is an important adverse predictor of glycemic ... "Microalbuminuria and risk of venous thromboembolism". JAMA: The Journal of the American Medical Association. 301 (17): 1790-7. ...
Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J (2021). "Combined Oral Contraceptives and Venous Thromboembolism: Review ... Tchaikovski SN, Rosing J (July 2010). "Mechanisms of estrogen-induced venous thromboembolism". Thromb Res. 126 (1): 5-11. doi: ...
Venous thromboembolism (VTE) is a serious but preventable condition that happens when blood clots form in deep veins in the ... Venous thromboembolism (VTE) is a condition that occurs when a blood clot forms in a vein. VTE includes deep vein thrombosis ( ...
Venous Thromboembolism: A Public Health ConcernExternal. *The Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis ...
Multiple myeloma is associated with a significant risk of venous thromboembolism (VTE), causing substantial levels of morbidity ... Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Zamagni E, Brioli A, Tacchetti P, Zannetti ... Nursing management of treatment-related venous thromboembolism in patients with multiple myeloma. Yang B, Liu C, Lin Z, Geng C ... Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special ...
Venous thromboembolism is an area in which we have the luxury of numerous clinical trials and systematic reviews; the ACP/AAFP ... Journal Article Management of Patients With Venous Thromboembolism After the Initial Treatment Period ... the American Academy of Family Physicians have developed a new practice guideline for the management of venous thromboembolism ...
The Estrogen in Venous Thromboembolism Trial (EVTET) was a randomized controlled trial (RCT) of menopausal hormone therapy in ... Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM (August 2018). "Risk of venous thromboembolism events in ... Lobo RA (May 2011). "Risk of venous thromboembolism by route of administration of estrogen". Menopause. 18 (5): 469-70. doi: ... Scarabin PY (August 2018). "Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal ...
Venous thromboembolism (VTE) risk stratification and percentage of patients for whom risk-appropriate VTE prophylaxis was ... CDC Grand Rounds: Preventing Hospital-Associated Venous Thromboembolism. This is another in a series of occasional MMWR reports ... Impact of a venous thromboembolism (VTE) prophylaxis "smart order set": improved compliance, fewer events. Am J Hematol 2013;88 ... Venous thromboembolism prevention guidelines for medical inpatients: mind the (implementation) gap. J Hosp Med 2013;8:582-8. ...
... deep venous thrombosis (DVT) and pulmonary embolism (PE) (see the image below). The spectrum of disease ranges from clinically ... Thromboembolism encompasses two interrelated conditions that are part of the same spectrum, ... encoded search term (Venous Thromboembolism (VTE)) and Venous Thromboembolism (VTE) What to Read Next on Medscape ... American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. ...
... is the most common type of venous thromboembolism (VTE). It occurs when a blood clot forms in a deep vein, usually in the lower ...
Excess body weight is a risk factor of recurrent venous thromboembolism. ... Our study end point was symptomatic recurrent venous thromboembolism. Results: A total of 168 patients had recurrent venous ... Overweight, obesity, and the risk of recurrent venous thromboembolism Arch Intern Med. 2008 Aug 11;168(15):1678-83. doi: ... Background: Excess body weight is a risk factor for a first venous thromboembolism. The impact of excess body weight on risk of ...
2002)‎. Air travel and venous thromboembolism.. Bulletin of the World Health Organization, 80 (‎5)‎, 403 - 406. World Health ...
Presents a risk assessment model for individual patient profiling of Venous thromboembolism risk. ... Preventing Venous Thromboembolism: Prophylactic Options for Patients at Different Risk Levels. by James P. Kahan, Marleen ... Venous thromboembolism (VTE) represents a frequent and serious disorder influenced by numerous factors, but no current risk ... Kahan, James P., Marleen Cornelis, Han de Vries, Ineke van Beusekom, and Vincent Wietlisbach, Preventing Venous Thromboembolism ...
... reports and observational studies have suggested that patients who take antipsychotic drugs have an increased risk of venous ... thromboembolism (VTE). Using a case-control design, Zornberg and Jick (Lancet 2000 356:1219-1223) evaluated patterns of ... Antipsychotic drugs and venous thromboembolism. Case reports and observational studies have suggested that patients who take ... antipsychotic drugs have an increased risk of venous thromboembolism (VTE). Using a case-control design, Zornberg and Jick ( ...
... venous thromboembolism (VTE) has been associated with Cushings syndrome and with persistent mental stress, two conditions ... Venous thromboembolism Is the Subject Area "Venous thromboembolism" applicable to this article? Yes. No. ...
The cost-effectiveness of venous thromboembolism risk assessment tools for hospital inpatients. ... The cost-effectiveness of venous thromboembolism risk assessment tools for hospital inpatients. ...
... has bagged successful results in a paediatric trial of venous thromboembolism (VTE). ...
Venous Thrombosis and Thromboembolism in the Elderly (R01) RFA-AG-07-002. NIA ... of venous thrombosis (VT) and venous thromboembolism (VTE) in the elderly. ... Title: Venous Thrombosis and Thromboembolism in the Elderly (R01). Announcement Type New ... and venous thromboembolism (VTE) in older persons. Information from the research supported by this initiative should improve ...
Venous Thromboembolism in Adult Hospitalizations - United States, 2007-2009 *↑ 19.0 19.1 19.2 Beckman MG, Hooper WC, Critchley ... Abbreviations: LDUH: low dose unfractionated heparin; LMWH: low molecular weight heparin; VTE: Venous thromboembolism ... Venous thromboembolism (VTE) may be classified into deep vein thrombosis (DVT) and pulmonary embolism (PE). Pulmonary embolism ... Implications for venous thromboembolism screening". JAMA. 277 (16): 1305-7. PMID 9109469.. CS1 maint: Multiple names: authors ...
This review examined the efficacy of different strategies for preventing venous blood clots during hospitalization. The most ... Practices to prevent venous thromboembolism: a brief review. Citation Text:. Lau BD, Haut ER. Practices to prevent venous ... Practices to prevent venous thromboembolism: a brief review. BMJ Qual Saf. 2014;23(3):187-95. doi:10.1136/bmjqs-2012-001782. ... The Johns Hopkins Venous Thromboembolism (VTE) Collaborative Studies and Implements Methods to Prevent Avoidable Cases of ...
What is venous thromboembolism?. Venous thromboembolism (VTE) is a clinical condition that usually starts when a blood clot ... Venous thromboembolism (VTE), which comprises deep vein thrombosis (DVT) and pulmonary embolism (PE), is the leading cause of ... How can venous thromboembolism be prevented?. VTE prophylaxis (preventive interventions) can be mechanical (e.g. elastic ... Can medicines prevent venous thromboembolism after weight-loss surgery?. ...
Venous Thromboembolism. Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream. ... All MeSH CategoriesDiseases CategoryCardiovascular DiseasesVascular DiseasesEmbolism and ThrombosisThromboembolismVenous ...
You have to enable JavaScript in your browsers settings in order to use the eReader.. Or try downloading the content offline. DOWNLOAD ...
Venous thromboembolism prophylactic and therapeutic practice guideline. S Afr Med J 2009; 99: 467-473. [ Links ]. ... Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159(5): 457 ... management of venous thromboembolism (VTE).1 VTE is a major cause of morbidity and mortality, as highlighted recently by the ... Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: ...
Ximelagatran prevented secondary venous thromboembolism Message subject: (Your Name) has forwarded a page to you from BMJ ...
Nearly half of all venous thromboembolism (VTE) events occur during or soon after hospitalizations.1 And who are the frontline ...
Venous thromboembolism treatment market demand and products, geography. This study presents market analysis, trends, and future ... Venous thromboembolism treatment market outlook - 2027. Venous thromboembolism (VTE) is a condition in which a blood clot forms ... Growing demand for venous thromboembolism treatment devices is anticipated to drive for venous thromboembolism treatment ... Venous Thromboembolism Treatment Market Start reading.. This Report and over 71,298+ more Reports, Available with Avenue ...
Preventing Venous Thromboembolism - Grand Rounds Webcast. May 1, 2013. Grand Rounds Presentation. Tuesday, January 15, at 1 p.m ... This session of Grand Rounds will explore Venous Thromboembolism (VTE), which consists of 2 related conditions caused by blood ... "Preventing Venous Thromboembolism" next Tuesday, January 15 1-2 PM, ET.. NBCA CEO Alan Brownstein said that "blood clots are a ...
The risk of venous thromboembolism (VTE) associated with combined oral contraceptives is not a new issue and the recent study ... These studies confirm with a sufficient power most of the previous conclusions relating to the risk of venous thromboembolism ... Vinogradova and colleagues analysed 68% of the cases of venous thromboembolism and 56% of the controls in the QResearch and ... Any use of combined oral contraceptive had a three-fold increased risk of venous thromboembolism. With the exception of ...
Are you familiar with the presentation and treatment of venous thromboembolism? Test yourself with this short quiz. ... Venous thromboembolism (VTE) comprises two types of serious blood clots: deep venous thrombosis (DVT) and pulmonary embolism ( ... Incidence and Impact of Anticoagulation-Associated Abnormal Menstrual Bleeding in Women After Venous Thromboembolism 1.0 CME / ... Fast Five Quiz: Test Your Knowledge of Venous Thromboembolism - Medscape - Dec 03, 2018. ...
The disease process that includes DVT and/or pulmonary embolism is called venous thromboembolism (VTE). Each year in the United ... The Problem: Healthcare-associated venous thromboembolism (blood clots) is a significant, deadly, costly, and growing public ... Title : CDC Grand Rounds: Preventing Hospital-Associated Venous Thromboembolism Personal Author(s) : Streiff, Michael B.;Brady ... Deep venous thrombosis (DVT) is a blood clot in a large vein, usually in the leg or pelvis. Sometimes a DVT detaches from the ...
Preventing Venous Thromboembolism - Delta Day - In Person Event. January 13, 2020 @ 8:30 am - 3:00 pm. ...
  • Venous thromboembolism (VTE) comprises two types of serious blood clots: deep venous thrombosis (DVT) and pulmonary embolism (PE). (medscape.com)
  • Deep vein thrombosis (also known as deep venous thrombosis or DVT and colloquially referred to as " economy class syndrome ") is the formation of a blood clot (" thrombus ") in a deep vein . (wikidoc.org)
  • 1233 patients who were ⩾18 years of age with symptomatic, objectively confirmed deep venous thrombosis (DVT) or pulmonary embolism (PE) and had received anticoagulant therapy for 6 months with no recurrent VTE event. (bmj.com)
  • In patients with deep venous thrombosis or pulmonary embolism receiving standard anticoagulant therapy for 6 months, ximelagatran reduced recurrent venous thromboembolism and did not increase bleeding. (bmj.com)
  • Based on high-quality evidence, the Cochrane review showed that combining IPC with pharmacologic prophylaxis was more effective than a single preventative measure for preventing deep venous thrombosis (DVT), and more effective than IPC alone for preventing pulmonary embolism (PE). (aafp.org)
  • defined as deep venous thrombosis [DVT] and pulmonary embolism [PE], or both) in high-risk patients. (aafp.org)
  • This study confirmed that the AHRQ patient safety indicator (PSI) for postoperative deep venous thrombosis (DVT) is best used as a screening tool for identifying preventable DVT cases from administrative data. (ahrq.gov)
  • Arixtra is approved in the United States (U.S.) for the prevention of venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients undergoing surgery for hip fracture (including extended prophylaxis), knee replacement, hip replacement, and in abdominal surgery patients who are at risk for thromboembolic complications. (webwire.com)
  • For high-risk patients, does prophylaxis against venous thromboembolism (VTE) with the combined modalities of leg intermittent pneumatic compression (IPC) and pharmacologic prophylaxis provide more protection than either treatment alone? (aafp.org)
  • This drug and the new very low molecular weight heparins - the pentasaccharides - are currently being evaluated in patients with ischaemic heart disease, atrial fibrillation and as prophylaxis and treatment of venous thromboembolism. (escardio.org)
  • Hospital-acquired venous thromboembolism (VTE) is a leading cause of preventable death in hospitalised patients and its prevention with pharmacological prophylaxis has been rated a top patient safety practice. (bmj.com)
  • At the time the CLOTS Trial Collaboration was reported, work was near completion on NICE guidance for venous thromboembolism (VTE) prophylaxis in all hospitalised patients. (bmj.com)
  • BACKGROUND: Evidence-based guidelines recommend that acutely ill hospitalized medical patients who are at risk of venous thromboembolism (VTE) should receive prophylaxis. (mcmaster.ca)
  • Our aim was to characterize the clinical practices for VTE prophylaxis in acutely ill hospitalized medical patients enrolled in the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE). (mcmaster.ca)
  • Research has shown that many hospitalized patients do not receive venous thromboembolism (VTE) prophylaxis despite being assessed as being at risk of VTE. (biomedcentral.com)
  • Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thrombo-embolism. (escardio.org)
  • Comparison of Low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. (escardio.org)
  • The Ottawa score is a clinical prediction rule designed for this purpose, stratifying patients according to their risk of recurrent venous thromboembolism during the first six months of anticoagulation. (haematologica.org)
  • The original score classified 49.3% of the patients as high-risk, with a sensitivity of 0.7 [95% confidence interval (CI): 0.6-0.8], a 6-month pooled rate of recurrent venous thromboembolism of 18.6% (95%CI: 13.9-23.9). (haematologica.org)
  • The modified score classified 19.8% of the patients as low-risk, with a sensitivity of 0.9 (95%CI: 0.4-1.0) and a 6-month pooled rate of recurrent venous thromboembolism of 2.2% (95%CI: 1.6-2.9). (haematologica.org)
  • Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. (umassmed.edu)
  • Illtyd James and Matheson in 1935 were the first in the Anglo-Saxon literature, at least to our knowledge, to report the observation of a patient with occult cancer at time of his venous thrombosis. (nih.gov)
  • Venous thromboembolism (VTE) may be classified into deep vein thrombosis ( DVT ) and pulmonary embolism ( PE ). (wikidoc.org)
  • Most often, pulmonary embolism is due to a venous thrombosis ( blood clot from a vein ), which has been dislodged from its site of formation in the lower extremities . (wikidoc.org)
  • Venous thromboembolism (VTE) includes deep-vein thrombosis (DVT), a blood clot that typically forms in the deep veins of the leg, and pulmonary embolism (PE), a life-threatening condition that occurs when a blood clot breaks free and becomes lodged in the arteries of the lung. (hematology.org)
  • Women with a personal history or a family history of venous thrombosis can be screened for risk factors to assist decision on the route of delivery for MHT. (menopause.org.au)
  • Venous thromboembolism, which includes both deep vein thrombosis (DVT) and PE, is a condition where a blood clot forms in a vein and may migrate to another location (e.g. the lung). (cochrane.org)
  • Venous thromboembolism (VTE) events, which manifest as deep vein thrombosis (DVT) and/or pulmonary embolism (PE), cause considerable mortality and morbidity. (ajmc.com)
  • A new study helps support a role for the new oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) in patients with venous thrombosis (VTE). (jwatch.org)
  • PHARMAC is interested in considering any proposal from suppliers of medical devices used in the prevention of venous thromboembolisms (VTEs), such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) for use in DHB Hospitals. (pharmac.govt.nz)
  • Increased risk for venous thrombosis was found among those under 50 having both lipid abnormalities. (who.int)
  • the development of venous thrombosis. (who.int)
  • Philadelphia, PA, February 3, 2006 Results from a new study of Arixtra (fondaparinux sodium) called FLEXTRA (Flexibility in Administration of Fondaparinux for Prevention of Symptomatic Venous Thromboembolism in Orthopaedic Surgery) showed the anti-thrombotic drug was generally well tolerated and effective in the prevention of symptomatic venous thromboembolism (VTE) when administered to patients the morning after orthopedic surgery. (webwire.com)
  • The frequency of symptomatic venous thromboembolism was 2.8 percent among those receiving ximelagatran, a rate that was 78 percent lower than in the placebo group. (escardio.org)
  • Q In patients with acute venous thromboembolism (VTE), is fixed dose subcutaneous low molecular weight heparin (LMWH) more effective than adjusted dose unfractionated heparin (UFH) for reducing symptomatic recurrent VTE? (bmj.com)
  • The characteristics of human genomics and cellular immune function between clinically symptomatic venous thromboembolism (VTE) and controls were systematically compared to explore the immunologic pathogenesis of VTE. (scienceopen.com)
  • WASHINGTON, August 10, 2021) - Today, the American Society of Hematology (ASH), the world's largest professional society dedicated to furthering the understanding, diagnosis, treatment, and prevention of blood disorders, announced the publication of adapted guidelines for the management of venous thromboembolism in Latin America, in partnership with 12 Latin American hematology societies representing 10 countries. (hematology.org)
  • Hospital acquired venous thromboembolism (VTE) is a major source of morbidity and mortality, yet proven prevention measures are often underutilized. (nih.gov)
  • Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. (bmj.com)
  • Q What is the long term efficacy and safety of ximelagatran after 6 months of standard anticoagulant therapy for secondary prevention of venous thromboembolism (VTE)? (bmj.com)
  • Oral ximelagatran is superior to placebo for extended prevention of venous thromboembolism in patients initially treated with warfarin (INR 2.0-3.0) for six months. (escardio.org)
  • Schulman et al showed that oral ximelagatran was superior to placebo for the extended prevention of venous thromboembolism and that there was no significant increase in the frequencies of bleeding complications (4). (escardio.org)
  • However, a direct comparison of ximelagatran and warfarin based on efficacy of the drugs, inconveniences in laboratory monitoring (INR, ALAT) and costs, is warranted, before any conclusion can be drawn as to the drug of choice in long-term prevention of venous thromboembolism. (escardio.org)
  • While waiting for such comparisons, extended prevention of venous thromboembolism with oral ximelagatran might be an option in some patients. (escardio.org)
  • 4) Schulman S, Wåhlander K, Lundström T, Clason S B, Erikson H, for the THRIVE III Investigators: Secondary prevention of venous thromboembolism with oral direct thrombin inhibitor Ximelagatran. (escardio.org)
  • Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (scienceopen.com)
  • This article discusses the prevention of venous thromboembolism (VTE) and is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (scienceopen.com)
  • PRINCETON, N.J. & NEW YORK--(Healthcare Sales & Marketing Network)-- The European Commission has approved ELIQUIS in the 27 countries of the European Union (EU) for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. (salesandmarketingnetwork.com)
  • PHARMAC invites proposals for the supply of medical devices used in the prevention of venous thromboembolisms (VTEs) to DHB hospitals in New Zealand. (pharmac.govt.nz)
  • ABSTRACT To assess the risk of venous thromboembolism (VTE) associated with hyperhomocystein- aemia (hyper-Hcy) and hyperlipidaemia, we performed a case-control study. (who.int)
  • When a blood clot breaks loose and travels in the blood, it is called a venous thrombo- embolism (VTE). (medindia.net)
  • The thrombotic effects of MHT containing oral oestrogen are associated with a slightly increased risk of stroke and venous thrombo-embolism (VTE) but not of coronary heart disease (3). (menopause.org.au)
  • Similarly, a small study found that transdermal estradiol did not influence coagulation in women with prior VTE, and the observational Menopause, Estrogen and Venous Events (MEVE) study found that transdermal estradiol was not associated with increased risk of VTE in postmenopausal women with past VTE (HRTooltip hazard ratio = 1.0 (95% CITooltip confidence interval 0.4-2.4) for transdermal estradiol vs. HR = 6.4 (95% CI 1.5-27.3) for oral estrogens). (wikipedia.org)
  • A diagnosis of cancer can leave you and your loved ones feeling uncertain, anxious and overwhelmed, especially if you are at risk of venous thromboembolism (VTE). (cancercare.org)
  • Venous thromboembolism (VTE) is a multifactorial disease driven by environmental/acquired risk factors such as age, obesity, oral contraceptives, and immobility, as well as inherited risk factors such as genetic polymorphisms. (medscape.com)
  • Antithrombin deficiency leads to the highest risk of venous thromboembolism among deficiencies of natural anticoagulants. (medscape.com)
  • Preliminary data from two Women's Health Initiative trials that assessed factors that indicate increased risk of venous thromboembolism (VTE) with postmenopausal hormone therapy is now available. (sciencedaily.com)
  • Chandra D, Parisini E, Mozaffarian D. Meta-analysis: travel and risk for venous thromboembolism. (unboundmedicine.com)
  • TY - JOUR T1 - Meta-analysis: travel and risk for venous thromboembolism. (unboundmedicine.com)
  • The risk for venous thromboembolism is increased in cancer patients, particularly in those receiving chemotherapy," explained the study's lead author, Judith S. Brand, PhD, a postdoctoral researcher in the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet in Stockholm, Sweden. (nursingcenter.com)
  • Objective To investigate the association between use of combined oral contraceptives and risk of venous thromboembolism, taking the type of progestogen into account. (bmj.com)
  • Current exposure to any combined oral contraceptive was associated with an increased risk of venous thromboembolism (adjusted odds ratio 2.97, 95% confidence interval 2.78 to 3.17) compared with no exposure in the previous year. (bmj.com)
  • Idiopathic venous thromboembolism is associated with a 5-7 % increased risk of recurrence after an initial six months of anticoagulation with conventional-intensity warfarin (INR 2.0-3.0), but can be reduced with the use of extended warfarin therapy (1). (escardio.org)
  • Over 8 million acute medically ill patients each year in the United States are at risk for experiencing venous thromboembolism (VTE) events, with up to 900,000 patients developing blood clots for the first time. (ajmc.com)
  • We conclude that new therapeutic strategies are needed in patients at high risk for recurrent cancer-associated venous thromboembolism. (haematologica.org)
  • Cancer is one of the most frequent risk factors for venous thromboembolism (VTE) and for VTE recurrence while on anticoagulation. (haematologica.org)
  • Analysis of incidence and risk factors for postoperative venous thromboembolism in patients with stageⅠ a non-small-cell lung cancer]. (physiciansweekly.com)
  • To analyze the incidence and risk factors for postoperative venous thromboembolism(VTE) in patients with stage Ⅰa non-small-cell lung cancer(NSCLC), so as to find evidence for further research of prophylactic anticoagulation. (physiciansweekly.com)
  • Venous thromboembolism (VTE) in patients with AAV is common with previous studies identifying a 4-fold increased risk in AAV compared with the general population. (researchsquare.com)
  • Little is known on the clinical characteristics, risk factors and outcomes during anticoagulation in young patients with acute venous thromboembolism (VTE). (efim.org)
  • Risk assessment and mortality prediction in patients with venous thromboembolism using big data and machine learning. (bournemouth.ac.uk)
  • Studies of the pathophysiologic mechanisms for the increased risk of VTE after long-distance travel have not produced consistent results, but venous stasis appears to play a major role. (cdc.gov)
  • Conventional risk factors such as surgery · for clot in the inferior vena cava, Dop- do not account for all cases, and only a pler sonography or computed tomogra- fraction of those with these risk factors phy with venous phase contrast. (who.int)
  • Background The risk for venous thromboembolism (VTE) is elevated with albuminuria or a low estimated glomerular filtration rate (eGFR). (medscape.com)
  • When used in the outpatient setting, anticoagulants (blood thinners) probably reduce venous thromboembolism (VTE) and pulmonary embolism (PE) when compared with placebo or no treatment in people with COVID-19. (cochrane.org)
  • Samantha Pettigrew, MD, second-year pulmonary critical care fellow at Temple University Hospital, participated in a video interview with Healio Pulmonology on the recent CHEST update on venous thromboembolism and anti-coagulation. (templehealth.org)
  • Fast Five Quiz: Test Your Knowledge of Venous Thromboembolism - Medscape - Dec 03, 2018. (medscape.com)
  • Clinical validation of the AHRQ postoperative venous thromboembolism patient safety indicator. (ahrq.gov)
  • Recently, Schulman and co-workers assessed a new treatment option, namely the effects of the oral direct thrombin inhibitor ximelagatran 24 mg twice daily or placebo in patients who had completed 6 months of anticoagulant therapy for an episode of venous thromboembolism. (escardio.org)
  • We know that we need to take a good history and do a physical exam in patients with venous thromboembolism. (oncologynurseadvisor.com)
  • In patients with cancer-associated venous thromboembolism, knowledge of the estimated rate of recurrent events is important for clinical decision-making regarding anticoagulant therapy. (haematologica.org)
  • Venous thromboembolism (VTE) is a common complication in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) and confers significant morbidity and mortality. (researchsquare.com)
  • Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in hospitalized patients. (biomedcentral.com)
  • Venous thromboembolism (VTE) is the third most common cardiovascular condition that affects mainly hospitalized and cancer patients and it is associated with high morbidity and mortality. (bournemouth.ac.uk)
  • Venous thromboembolism (VTE) as the most common cancer -associated complication has become the second death -causing reason among cancer patients . (bvsalud.org)
  • L'objectif de ce travail était de décrire le profi l des manifestations cardiovasculaires chez les patients vivants avec le VIH en le comparant à celui de patients séronégatifs. (bvsalud.org)
  • Participants Women aged 15-49 years with a first diagnosis of venous thromboembolism in 2001-13, each matched with up to five controls by age, practice, and calendar year. (bmj.com)
  • Venous thromboembolism is a common complication of total knee or hip replacement surgery. (webwire.com)
  • The Estrogen in Venous Thromboembolism Trial (EVTET) was a randomized controlled trial (RCT) of menopausal hormone therapy in 140 postmenopausal women with previous history of venous thromboembolism (VTE). (wikipedia.org)
  • Menopause, Estrogen and Venous Events (MEVE) List of notable clinical studies of menopausal hormone therapy Høibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrøm E, Sandset PM (December 2000). (wikipedia.org)
  • Venous thromboembolism is a major cause of morbidity and mortality in the United States, affecting up to 900,000 people and accounting for up to 100,000 deaths annually. (wayne.edu)
  • Venous thromboembolism (VTE), also known as blood clots, is an underdiagnosed and serious, but preventable medical condition. (cdc.gov)
  • Venous thromboembolism (VTE) is regarded as the most preventable cause of inpatient death in hospital settings globally. (bvsalud.org)
  • Results 5062 cases of venous thromboembolism from CPRD and 5500 from QResearch were analysed. (bmj.com)
  • COVID-19 and Venous Thromboembolism: What Role Do Clotting and Anticoagulation Play in the Disease? (vumedi.com)
  • Venous thromboembolism (VTE) refers to a blood clot in a vein. (cancercare.org)
  • Venous thromboembolism, or VTE, is a condition in which blood clots form in veins that are deep inside the body. (planetdrugsdirect.com)
  • Venous thromboembolism (VTE) is a blood clot that can develop in the deep veins of the body, most commonly in the leg. (hey.nhs.uk)
  • Venous thromboembolism (VTE) refers to DVT, PE, or both. (cdc.gov)
  • Trousseau is considered to be the first to have recognised a relation between venous thromboembolism (VTE) and malignancy. (nih.gov)
  • Main outcome measures Odds ratios for incident venous thromboembolism and use of combined oral contraceptives in the previous year, adjusted for smoking status, alcohol consumption, ethnic group, body mass index, comorbidities, and other contraceptive drugs. (bmj.com)
  • E-learning course on the treatment and management of venous thromboembolism. (cdc.gov)
  • Details for: Pharmacological treatment of venous thromboembolism. (who.int)
  • Conclusions In these population based, case-control studies using two large primary care databases, risks of venous thromboembolism associated with combined oral contraceptives were, with the exception of norgestimate, higher for newer drug preparations than for second generation drugs. (bmj.com)
  • Free continuing education for healthcare providers: Learn about venous thromboembolism in this e-learning course. (cdc.gov)
  • Although combined oral contraceptives are generally effective in preventing pregnancy, they have measurable side effects such as venous thromboembolism (VTE). (bmj.com)
  • Unfortunately, venous thromboembolism is very common. (planetdrugsdirect.com)
  • OBJECTIVES: Venous thromboembolism (VTE) is a common worldwide disease. (lu.se)